Adrenergic receptor

ABSTRACT

A human adrenergic receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are agonists for the adrenergic receptor polypeptide which may be used therapeutically to stimulate the adrenergic receptor and antagonist inhibitors against such adrenergic receptor polypeptides and their use therapeutically to antagonize the adrenergic receptor.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent applicationSer. No. 09/951,622, filed Sep. 14, 2001, which is a continuation ofU.S. patent application Ser. No. 09/339,244, filed Jun. 24, 1999, whichis a divisional of U.S. patent application Ser. No. 09/030,582, filedFeb. 25, 1998, now U.S. Pat. No. 5,994,506, which is a divisional ofU.S. patent application Ser. No. 08/467,568, filed Jun. 6, 1995, nowU.S. Pat. No. 5,817,477, which is a continuation-in-part ofInternational Application No. PCT/US94/09051, filed Aug. 10, 1994 whichwas published by the International Bureau as International PublicationNo. WO96/05225 on Feb. 22, 1996 in English.

BACKGROUND OF THE INVENTION

[0002] This invention relates to newly identified polynucleotides,polypeptides encoded by such polynucleotides, the use of suchpolynucleotides and polypeptides, as well as the production of suchpolynucleotides and polypeptides. More particularly, the polypeptide ofthe present invention is a human 7-transmembrane receptor. Thetransmembrane receptor is a G-protein coupled receptor. Moreparticularly, the 7-transmembrane receptor has been putativelyidentified as an adrenergic receptor. The invention also relates toinhibiting the action of such polypeptides.

[0003] It is well established that many medically significant biologicalprocesses are mediated by proteins participating in signal transductionpathways that involve G-proteins and/or second messengers, e.g., cAMP(Lefkowitz, Nature, 351:353-354 (1991)). Herein these proteins arereferred to as proteins participating in pathways with G-proteins or PPGproteins. Some examples of these proteins include the GPC receptors,such as those for adrenergic agents and dopamine (Kobilka, B. K., etal., Pnas, 84:46-50 (1987); Kobilka, B. K., et al., Science, 238:650-656(1987); Bunzow, J. R., et al., Nature, 336:783-787 (1988)), G-proteinsthemselves, effector proteins, e.g., phospholipase C, adenyl cyclase,and phosphodiesterase, and actuator proteins, e.g., protein kinase A andprotein kinase C (Simon, M. I., et al., Science, 252:802-8 (1991)).

[0004] For example, in one form of signal transductions, the effect ofhormone binding is activation of an enzyme, adenylate cyclase, insidethe cell. Enzyme activation by hormones is dependent on the presence ofthe nucleotide GTP, and GTP also influences hormone binding. A G-proteinconnects the hormone receptors to adenylate cyclase. G-protein was shownto exchange GTP for bound GDP when activated by hormone receptors. TheGTP-carrying form then binds to an activated adenylate cyclase.Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns theG-protein to its basal, inactive form. Thus, the G-protein serves a dualrole, as an intermediate that relays the signal from receptor toeffector, and as a clock that controls the duration of the signal.

[0005] The adrenergic receptors comprise one of the largest and mostextensively characterized families within the G-protein coupled receptor“superfamily”. This superfamily includes not only adrenergic receptors,but also muscarinic, cholinergic, dopaminergic, serotonergic, andhistaminergic receptors. Numerous peptide receptors include glucagon,somatostatin, and vasopressin receptors, as well as sensory receptorsfor vision (rhodopsin), taste, and olfaction, also belong to thisgrowing family. Despite the diversity of signalling molecules, G-proteincoupled receptors all possess a similar overall primary structure,characterized by 7 putative membrane-spanning a helices (Probst et al.,1992). In the most basic sense, the adrenergic receptors are thephysiological sites of action of the catecholamines, epinephrine andnorepinephrine. Adrenergic receptors were initially classified as eitherα or β by Ahlquist, who demonstrated that the order of potency for aseries of agonists to evoke a physiological response was distinctlydifferent at the 2 receptor subtypes (Ahlquist, 1948). Functionally, αadrenergic receptors were shown to control vasoconstriction, pupildilation and uterine inhibition, while β adrenergic receptors wereimplicated in vasorelaxation, myocardial stimulation and bronchodilation(Regan et al., 1990). Eventually, pharmacologists realized that theseresponses resulted from activation of several distinct adrenergicreceptor subtypes. β adrenergic receptors in the heart were defined asβ₁, while those in the lung and vasculature were termed β₂ (Lands etal., 1967).

[0006] α Adrenergic receptors, meanwhile, were first classified based ontheir anatomical location, as either pre or post-synaptic (α₂ and α₁,respectively) (Langer et al., 1974). This classification scheme wasconfounded, however, by the presence of α₂ receptors in distinctlynon-synaptic locations, such as platelets (Berthelsen and Pettinger,1977). With the development of radioligand binding techniques, αadrenergic receptors could be distinguished pharmacologically based ontheir affinities for the antagonists prazosin or yohimbine (Stark,1981). Definitive evidence for adrenergic receptor subtypes, however,awaited purification and molecular cloning of adrenergic receptorsubtypes. In 1986, the genes for the hamster β₂ (Dickson et al., 1986)and turkey β₁ adrenergic receptors (Yarden et al., 1986) were cloned andsequenced. Hydropathy analysis revealed that these proteins contain 7hydrophobic domains similar to rhodopsin, the receptor for light. Sincethat time the adrenergic receptor family has expanded to include 3subtypes of β receptors (Emorine et al., 1989), 3 subtypes of α₁receptors (Schwinn et al., 1990), and 3 distinct types of α₂ receptors(Lomasney et al., 1990).

[0007] The α₂ receptors appear to have diverged rather early from eitherβ or α₁ receptors. The α₂ receptors have been broken down into 3molecularly distinct subtypes termed α₂C2, α₂C4, and α₂C10 based ontheir chromosomal location. These subtypes appear to correspond to thepharmacologically defined α_(2B), α_(2C), and α_(2A) subtypes,respectively (Bylund et al., 1992). While all the receptors of theadrenergic type are recognized by epinephrine, they arepharmacologically distinct and are encoded by separate genes. Thesereceptors are generally coupled to different second messenger pathwaysthat are linked through G-proteins. Among the adrenergic receptors, β₁and β₂ receptors activate the adenylate cyclase, α₂ receptors inhibitadenylate cyclase and α₁ receptors activate phospholipase C pathways,stimulating breakdown of polyphosphoinositides (Chung, F. Z. et al., J.Biol. Chem., 263:4052 (1988)). α₁ and α₂ adrenergic receptors differ intheir cell activity for drugs.

SUMMARY OF THE INVENTION

[0008] In accordance with one aspect of the present invention, there areprovided novel polypeptides which have been putatively identified asadrenergic receptors, as well as fragments, analogs and derivativesthereof. The polypeptides of the present invention are of human origin.

[0009] In accordance with another aspect of the present invention, thereare provided polynucleotides (DNA or RNA) which encode suchpolypeptides.

[0010] In accordance with a further aspect of the present invention,there is provided a process for producing such polypeptides byrecombinant techniques.

[0011] In accordance with yet a further aspect of the present invention,there are provided antibodies against such polypeptides.

[0012] In accordance with another embodiment, there is provided aprocess for using the receptor to screen for receptor antagonists and/oragonists and/or receptor ligands.

[0013] In accordance with still another embodiment of the presentinvention there is provided a process of using such agonists fortherapeutic purposes, for example, to treat upper respiratoryconditions.

[0014] In accordance with another aspect of the present invention thereis provided a process of using such antagonists for treatinghypertension.

[0015] These and other aspects of the present invention should beapparent to those skilled in the art from the teachings herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The following drawings are illustrative of embodiments of theinvention and are not meant to limit the scope of the invention asencompassed by the claims.

[0017] FIGS. 1A-E show the cDNA sequence (SEQ ID NO:1) and thecorresponding deduced amino acid sequence (SEQ ID NO:2) of the G-proteincoupled receptor of the present invention. The standard one-letterabbreviation for amino acids is used.

[0018] FIGS. 2A1-2A3, 2B1-2B3 and 2C1-2C3 illustrate an amino acidalignment of the G-protein coupled receptor of the present invention andadrenergic receptors from various species of animals. Faded areas arethose areas which match with the other amino acid sequences in thefigure. The comparative polypeptide sequences are represented byone-letter amino acid codes and each comparative row has five sets oflines representing the five amino acid sequences SEQ ID NOS: 9-13,respectively.

DETAILED DESCRIPTION OF THE INVENTION

[0019] It should be pointed out that sequencing inaccuracies are acommon problem which occurs in polynucleotide sequences. Accordingly,the sequence of the drawing is based on several sequencing runs and thesequencing accuracy is considered to be at least 97%.

[0020] In accordance with an aspect of the present invention, there isprovided an isolated nucleic acid (polynucleotide) which encodes for themature polypeptide having the deduced amino acid sequence of FIGS. 1A-Eor for the mature polypeptide encoded by the cDNA of the clone depositedas ATCC Deposit No. 75822 on Jun. 24, 1994.

[0021] The ATCC number referred to above is directed to a biologicaldeposit with the American Type Culture Collection (ATCC) 10801University Boulevard, Manassas, Va. 20110-2209. The strain is beingmaintained under the terms of the Budapest Treaty and will be madeavailable to a patent office signatory to the Budapest Treaty.

[0022] A polynucleotide encoding a polypeptide of the present inventionmay be found in the brain, lung, pancreas and kidney. The polynucleotideof this invention was discovered in a cDNA library derived from a humaninfant brain. It is structurally related to the al adrenergic receptorfamily. It contains an open reading frame encoding a protein of 529amino acid residues. The protein exhibits the highest degree of homologyto α_(1C) at the nucleotide sequence level and α_(1B) at the amino acidlevel with 30% identity and 47% similarity over a 500 amino acidstretch.

[0023] The polynucleotide of the present invention may be in the form ofRNA or in the form of DNA, which DNA includes cDNA, genomic DNA, andsynthetic DNA. The DNA may be double-stranded or single-stranded, and ifsingle stranded may be the coding strand or non-coding (anti-sense)strand. The coding sequence which encodes the mature polypeptide may beidentical to the coding sequence shown in FIGS. 1A-E (SEQ ID NO:1) orthat of the deposited clone or may be a different coding sequence whichcoding sequence, as a result of the redundancy or degeneracy of thegenetic code, encodes the same mature polypeptide as the DNA of FIGS.1A-E (SEQ ID NO:1) or the deposited cDNA.

[0024] The polynucleotide which encodes for the mature polypeptide ofFIGS. 1A-E (SEQ ID NO:2) or for the mature polypeptide encoded by thedeposited cDNA may include: only the coding sequence for the maturepolypeptide; the coding sequence for the mature polypeptide andadditional coding sequence such as a leader or secretory sequence or aproprotein sequence; the coding sequence for the mature polypeptide (andoptionally additional coding sequence) and non-coding sequence, such asintrons or non-coding sequence 5′ and/or 3′ of the coding sequence forthe mature polypeptide.

[0025] Thus, the term “polynucleotide encoding a polypeptide”encompasses a polynucleotide which includes only coding sequence for thepolypeptide as well as a polynucleotide which includes additional codingand/or non-coding sequence.

[0026] The present invention further relates to variants of thehereinabove described polynucleotides which encode for fragments,analogs and derivatives of the polypeptide having the deduced amino acidsequence of FIGS. 1A-E (SEQ ID NO:2) or the polypeptide encoded by thecDNA of the deposited clone. The variant of the polynucleotide may be anaturally occurring allelic variant of the polynucleotide or anon-naturally occurring variant of the polynucleotide.

[0027] Thus, the present invention includes polynucleotides encoding thesame mature polypeptide as shown in FIGS. 1A-E (SEQ ID NO:2) or the samemature polypeptide encoded by the cDNA of the deposited clone as well asvariants of such polynucleotides which variants encode for a fragment,derivative or analog of the polypeptide of FIGS. 1A-E (SEQ ID NO:2) orthe polypeptide encoded by the cDNA of the deposited clone. Suchnucleotide variants include deletion variants, substitution variants andaddition or insertion variants.

[0028] As hereinabove indicated, the polynucleotide may have a codingsequence which is a naturally occurring allelic variant of the codingsequence shown in FIGS. 1A-E (SEQ ID NO:1) or of the coding sequence ofthe deposited clone. As known in the art, an allelic variant is analternate form of a polynucleotide sequence which may have asubstitution, deletion or addition of one or more nucleotides, whichdoes not substantially alter the function of the encoded polypeptide.

[0029] The polynucleotides may also encode for a soluble form of thereceptor polypeptide which is the extracellular portion of thepolypeptide which has been cleaved from the TM and intracellular domainof the full-length polypeptide of the present invention.

[0030] The polynucleotides of the present invention may also have thecoding sequence fused in frame to a marker sequence which allows forpurification of the polypeptide of the present invention. The markersequence may be a hexa-histidine tag supplied by a pQE-9 vector toprovide for purification of the mature polypeptide fused to the markerin the case of a bacterial host, or, for example, the marker sequencemay be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells,is used. The HA tag corresponds to an epitope derived from the influenzahemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

[0031] The term “gene” means the segment of DNA involved in producing apolypeptide chain; it includes regions preceding and following thecoding region (leader and trailer) as well as intervening sequences(introns) between individual coding segments (exons).

[0032] Fragments of the full length gene of the present invention may beused as a hybridization probe for a cDNA library to isolate the fulllength cDNA and to isolate other cDNAs which have as high sequencesimilarity to the gene or similar biological activity. Probes of thistype preferably have at least 30 bases and may contain, for example, 50or more bases. The probe may also be used to identify a cDNA clonecorresponding to a full length transcript and a genomic clone or clonesthat contain the complete gene including regulatory and promotorregions, exons, and introns. An example of a screen comprises isolatingthe coding region of the gene by using the known DNA sequence tosynthesize an oligonucleotide probe. Labeled oligonucleotides having asequence complementary to that of the gene of the present invention areused to screen a library of human cDNA, genomic DNA or mRNA to determinewhich members of the library the probe hybridizes to.

[0033] The present invention further relates to polynucleotides whichhybridize to the hereinabove-described sequences if there is at least70%, preferably at least 90%, and more preferably at least 95% identitybetween the sequences. The present invention particularly relates topolynucleotides which hybridize under stringent conditions to thehereinabove-described polynucleotides. As herein used, the term“stringent conditions” means hybridization will occur only if there isat least 95% and preferably at least 97% identity between the sequences.The polynucleotides which hybridize to the hereinabove describedpolynucleotides in a preferred embodiment encode polypeptides whicheither retain substantially the same biological function or activity asthe mature polypeptide encoded by the cDNA of FIGS. 1A-E (SEQ ID NO:1)or the deposited cDNA(s).

[0034] Alternatively, the polynucleotide may have at least 20 bases,preferably 30 bases, and more preferably at least 50 bases whichhybridize to a polynucleotide of the present invention and which has anidentity thereto, as hereinabove described, and which may or may notretain activity. For example, such polynucleotides may be employed asprobes for the polynucleotide of SEQ ID NO:1, for example, for recoveryof the polynucleotide or as a diagnostic probe or as a PCR primer.

[0035] Thus, the present invention is directed to polynucleotides havingat least a 70% identity, preferably at least 90% and more preferably atleast a 95% identity to a polynucleotide which encodes the polypeptideof SEQ ID NO:2 as well as fragments thereof, which fragments have atleast 30 bases and preferably at least 50 bases and to polypeptidesencoded by such polynucleotides.

[0036] The deposit(s) referred to herein will be maintained under theterms of the Budapest Treaty on the International Recognition of theDeposit of Micro-organisms for purposes of Patent Procedure. Thesedeposits are provided merely as convenience to those of skill in the artand are not an admission that a deposit is required under 35 U.S.C.§112. The sequence of the polynucleotides contained in the depositedmaterials, as well as the amino acid sequence of the polypeptidesencoded thereby, are incorporated herein by reference and arecontrolling in the event of any conflict with any description ofsequences herein. A license may be required to make, use or sell thedeposited materials, and no such license is hereby granted.

[0037] The present invention further relates to a receptor polypeptidewhich has the deduced amino acid sequence of FIGS. 1A-E (SEQ ID NO:2) orwhich has the amino acid sequence encoded by the deposited cDNA, as wellas fragments, analogs and derivatives of such polypeptide.

[0038] The terms “fragment,” “derivative” and “analog” when referring tothe polypeptide of FIGS. 1A-E (SEQ ID NO:2) or that encoded by thedeposited cDNA, means a polypeptide which either retains substantiallythe same biological function or activity as such polypeptide, i.e.functions as a receptor, or retains the ability to bind the ligand forthe receptor even though the polypeptide does not function as aG-protein coupled receptor, for example, a soluble form of the receptor.

[0039] The polypeptide of the present invention may be a recombinantpolypeptide, a natural polypeptide or a synthetic polypeptide,preferably a recombinant polypeptide.

[0040] The fragment, derivative or analog of the polypeptide of FIGS.1A-E (SEQ ID NO:2) or that encoded by the deposited cDNA may be (i) onein which one or more of the amino acid residues are substituted with aconserved or non-conserved amino acid residue (preferably a conservedamino acid residue) and such substituted amino acid residue may or maynot be one encoded by the genetic code, or (ii) one in which one or moreof the amino acid residues includes a substituent group, or (iii) one inwhich the mature polypeptide is fused with another compound, such as acompound to increase the half-life of the polypeptide (for example,polyethylene glycol), or (iv) one in which the additional amino acidsare fused to the mature polypeptide which are employed for purificationof the mature polypeptide or a proprotein sequence or (v) one in which afragment of the polypeptide is soluble, i.e., not membrane bound, yetstill binds ligands to the membrane bound receptor. Such fragments,derivatives and analogs are deemed to be within the scope of thoseskilled in the art from the teachings herein.

[0041] The polypeptides and polynucleotides of the present invention arepreferably provided in an isolated form, and preferably are purified tohomogeneity.

[0042] The term “gene” means the segment of DNA involved in producing apolypeptide chain; it includes regions preceding and following thecoding region “leader and trailer” as well as intervening sequences(introns) between individual coding segments (exons).

[0043] The term “isolated” means that the material is removed from itsoriginal environment (e.g., the natural environment if it is naturallyoccurring). For example, a naturally-occurring polynucleotide orpolypeptide present in a living animal is not isolated, but the samepolynucleotide or polypeptide, separated from some or all of thecoexisting materials in the natural system, is isolated. Suchpolynucleotides could be part of a vector and/or such polynucleotides orpolypeptides could be part of a composition, and still be isolated inthat such vector or composition is not part of its natural environment.

[0044] The polypeptides of the present invention include the polypeptideof SEQ ID NO:2 (in particular the mature polypeptide) as well aspolypeptides which have at least 70% similarity (preferably at least 70%identity) to the polypeptide of SEQ ID NO:2 and more preferably at least90% similarity (preferably at least 90% identity) to the polypeptide ofSEQ ID NO:2 and still more preferably at least 95% similarity(preferably at least 95% identity) to the polypeptide of SEQ ID NO:2 andalso include portions of such polypeptides with such portion of thepolypeptide generally containing at least 30 amino acids and morepreferably at least 50 amino acids.

[0045] As known in the art “similarity” between two polypeptides isdetermined by comparing the amino acid sequence and its conserved aminoacid substitutes of one polypeptide to the sequence of a secondpolypeptide

[0046] Fragments or portions of the polypeptide of the present inventionmay be employed for producing the corresponding full-length polypeptideby peptide synthesis; therefore, the fragments may be employed asintermediates for producing the full-length polypeptides. Fragments orportions of the polynucleotides of the present invention may be used tosynthesize full-length polynucleotides of the present invention.

[0047] The present invention also relates to vectors which includepolynucleotides of the present invention, host cells which aregenetically engineered with vectors of the invention and the productionof polypeptides of the invention by recombinant techniques.

[0048] Host cells are genetically engineered (transduced or transformedor transfected) with the vectors of this invention which may be, forexample, a cloning vector or an expression vector. The vector may be,for example, in the form of a plasmid, a viral particle, a phage, etc.The engineered host cells can be cultured in conventional nutrient mediamodified as appropriate for activating promoters, selectingtransformants or amplifying the genes of the present invention. Theculture conditions, such as temperature, pH and the like, are thosepreviously used with the host cell selected for expression, and will beapparent to the ordinarily skilled artisan.

[0049] The polynucleotides of the present invention may be employed forproducing polypeptides by recombinant techniques. Thus, for example, thepolynucleotide may be included in any one of a variety of expressionvectors for expressing a polypeptide. Such vectors include chromosomal,nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40;bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectorsderived from combinations of plasmids and phage DNA, viral DNA such asvaccinia, adenovirus, fowl pox virus, and pseudorabies. However, anyother vector may be used as long as it is replicable and viable in thehost.

[0050] The appropriate DNA sequence may be inserted into the vector by avariety of procedures. In general, the DNA sequence is inserted into anappropriate restriction endonuclease site(s) by procedures known in theart. Such procedures and others are deemed to be within the scope ofthose skilled in the art.

[0051] The DNA sequence in the expression vector is operatively linkedto an appropriate expression control sequence(s) (promoter) to directmRNA synthesis. As representative examples of such promoters, there maybe mentioned: LTR or SV40 promoter, the E. coli. lac or trp, the phagelambda P_(L) promoter and other promoters known to control expression ofgenes in prokaryotic or eukaryotic cells or their viruses. Theexpression vector also contains a ribosome binding site for translationinitiation and a transcription terminator. The vector may also includeappropriate sequences for amplifying expression.

[0052] In addition, the expression vectors preferably contain one ormore selectable marker genes to provide a phenotypic trait for selectionof transformed host cells such as dihydrofolate reductase or neomycinresistance for eukaryotic cell culture, or such as tetracycline orampicillin resistance in E. coli.

[0053] The vector containing the appropriate DNA sequence as hereinabovedescribed, as well as an appropriate promoter or control sequence, maybe employed to transform an appropriate host to permit the host toexpress the protein.

[0054] As representative examples of appropriate hosts, there may bementioned: bacterial cells, such as E. coli, Streptomyces, Salmonellatyphimurium; fungal cells, such as yeast; insect cells such asDrosophila and Sf9; animal cells such as CHO, COS or Bowes melanoma;plant cells, etc. The selection of an appropriate host is deemed to bewithin the scope of those skilled in the art from the teachings herein.

[0055] More particularly, the present invention also includesrecombinant constructs comprising one or more of the sequences asbroadly described above. The constructs comprise a vector, such as aplasmid or viral vector, into which a sequence of the invention has beeninserted, in a forward or reverse orientation. In a preferred aspect ofthis embodiment, the construct further comprises regulatory sequences,including, for example, a promoter, operably linked to the sequence.Large numbers of suitable vectors and promoters are known to those ofskill in the art, and are commercially available. The following vectorsare provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen),pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a,pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5(Pharmacia). Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene)pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid orvector may be used as long as they are replicable and viable in thehost.

[0056] Promoter regions can be selected from any desired gene using CAT(chloramphenicol transferase) vectors or other vectors with selectablemarkers. Two appropriate vectors are PKK232-8 and PCM7. Particular namedbacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_(R), P_(L)and trp. Eukaryotic promoters include CMV immediate early, HSV thymidinekinase, early and late SV40, LTRs from retrovirus, and mousemetallothionein-I. Selection of the appropriate vector and promoter iswell within the level of ordinary skill in the art.

[0057] In a further embodiment, the present invention relates to hostcells containing the above-described constructs. The host cell can be ahigher eukaryotic cell, such as a mammalian cell, or a lower eukaryoticcell, such as a yeast cell, or the host cell can be a prokaryotic cell,such as a bacterial cell. Introduction of the construct into the hostcell can be effected by calcium phosphate transfection, DEAE-Dextranmediated transfection, or electroporation. (Davis, L., Dibner, M.,Battey, I., Basic Methods in Molecular Biology, (1986)).

[0058] The constructs in host cells can be used in a conventional mannerto produce the gene product encoded by the recombinant sequence.Alternatively, the polypeptides of the invention can be syntheticallyproduced by conventional peptide synthesizers.

[0059] Mature proteins can be expressed in mammalian cells, yeast,bacteria, or other cells under the control of appropriate promoters.Cell-free translation systems can also be employed to produce suchproteins using RNAs derived from the DNA constructs of the presentinvention. Appropriate cloning and expression vectors for use withprokaryotic and eukaryotic hosts are described by Sambrook, et al.,Molecular Cloning: A Laboratory Manual, Second Edition, Cold SpringHarbor, N.Y., (1989), the disclosure of which is hereby incorporated byreference.

[0060] Transcription of the DNA encoding the polypeptides of the presentinvention by higher eukaryotes is increased by inserting an enhancersequence into the vector. Enhancers are cis-acting elements of DNA,usually about from 10 to 300 bp that act on a promoter to increase itstranscription. Examples including the SV40 enhancer on the late side ofthe replication origin bp 100 to 270, a cytomegalovirus early promoterenhancer, the polyoma enhancer on the late side of the replicationorigin, and adenovirus enhancers.

[0061] Generally, recombinant expression vectors will include origins ofreplication and selectable markers permitting transformation of the hostcell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiaeTRP1 gene, and a promoter derived from a highly-expressed gene to directtranscription of a downstream structural sequence. Such promoters can bederived from operons encoding glycolytic enzymes such as3-phosphoglycerate kinase (PGK), α-factor, acid phosphatase, or heatshock proteins, among others. The heterologous structural sequence isassembled in appropriate phase with translation initiation andtermination sequences, and preferably, a leader sequence capable ofdirecting secretion of translated protein into the periplasmic space orextracellular medium. Optionally, the heterologous sequence can encode afusion protein including an N-terminal identification peptide impartingdesired characteristics, e.g., stabilization or simplified purificationof expressed recombinant product.

[0062] Useful expression vectors for bacterial use are constructed byinserting a structural DNA sequence encoding a desired protein togetherwith suitable translation initiation and termination signals in operablereading phase with a functional promoter. The vector will comprise oneor more phenotypic selectable markers and an origin of replication toensure maintenance of the vector and to, if desirable, provideamplification within the host. Suitable prokaryotic hosts fortransformation include E. coli, Bacillus subtilis, Salmonellatyphimurium and various species within the genera Pseudomonas,Streptomyces, and Staphylococcus, although others may also be employedas a matter of choice.

[0063] As a representative but nonlimiting example, useful expressionvectors for bacterial use can comprise a selectable marker and bacterialorigin of replication derived from commercially available plasmidscomprising genetic elements of the well known cloning vector pBR322(ATCC 37017). Such commercial vectors include, for example, pKK223-3(Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec,Madison, Wis., USA). These pBR322 “backbone” sections are combined withan appropriate promoter and the structural sequence to be expressed.

[0064] Following transformation of a suitable host strain and growth ofthe host strain to an appropriate cell density, the selected promoter isinduced by appropriate means (e.g., temperature shift or chemicalinduction) and cells are cultured for an additional period.

[0065] Cells are typically harvested by centrifugation, disrupted byphysical or chemical means, and the resulting crude extract retained forfurther purification.

[0066] Microbial cells employed in expression of proteins can bedisrupted by any convenient method, including freeze-thaw cycling,sonication, mechanical disruption, or use of cell lysing agents, suchmethods are well know to those skilled in the art.

[0067] Various mammalian cell culture systems can also be employed toexpress recombinant protein. Examples of mammalian expression systemsinclude the COS-7 lines of monkey kidney fibroblasts, described byGluzman, Cell, 23:175 (1981), and other cell lines capable of expressinga compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK celllines. Mammalian expression vectors will comprise an origin ofreplication, a suitable promoter and enhancer, and also any necessaryribosome binding sites, polyadenylation site, splice donor and acceptorsites, transcriptional termination sequences, and 5′ flankingnontranscribed sequences. DNA sequences derived from the SV40 splice,and polyadenylation sites may be used to provide the requirednontranscribed genetic elements.

[0068] The receptor polypeptides can be recovered and purified fromrecombinant cell cultures by methods including ammonium sulfate orethanol precipitation, acid extraction, anion or cation exchangechromatography, phosphocellulose chromatography, hydrophobic interactionchromatography, affinity chromatography hydroxylapatite chromatographyand lectin chromatography. Protein refolding steps can be used, asnecessary, in completing configuration of the mature protein. Finally,high performance liquid chromatography (HPLC) can be employed for finalpurification steps.

[0069] The polypeptides of the present invention may be a naturallypurified product, or a product of chemical synthetic procedures, orproduced by recombinant techniques from a prokaryotic or eukaryotic host(for example, by bacterial, yeast, higher plant, insect and mammaliancells in culture). Depending upon the host employed in a recombinantproduction procedure, the polypeptides of the present invention may beglycosylated or may be non-glycosylated. Polypeptides of the inventionmay also include an initial methionine amino acid residue.

[0070] The polynucleotides and polypeptides of the present invention maybe employed as research reagents and materials for discovery oftreatments and diagnostics to human disease.

[0071] The G-protein coupled receptor of the present invention may beemployed in a process for screening for antagonists and/or agonists forthe receptor.

[0072] In general, such screening procedures involve providingappropriate cells which express the receptor on the surface thereof. Inparticular, a polynucleotide encoding the receptor of the presentinvention is employed to transfect cells to thereby express theG-protein coupled receptor. Such transfection may be accomplished byprocedures as hereinabove described.

[0073] One such screening procedure involves the use of the melanophoreswhich are transfected to express the G-protein coupled receptor of thepresent invention. Such a screening technique is described in PCT WO92/01810 published Feb. 6, 1992.

[0074] Thus, for example, such assay may be employed for screening for areceptor antagonist by contacting the melanophore cells which encode theG-protein coupled receptor with both the receptor ligand and a compoundto be screened. Inhibition of the signal generated by the ligandindicates that a compound is a potential antagonist for the receptor,i.e., inhibits activation of the receptor.

[0075] The screen may be employed for determining an agonist bycontacting such cells with compounds to be screened and determiningwhether such compound generates a signal, i.e., activates the receptor.

[0076] Other screening techniques include the use of cells which expressthe G-protein coupled receptor (for example, transfected CHO cells) in asystem which measures extracellular pH changes caused by receptoractivation, for example, as described in Science, volume 246, pages181-296 (October 1989). For example, potential agonists or antagonistsmay be contacted with a cell which expresses the G-protein coupledreceptor and a second messenger response, e.g. signal transduction or pHchanges, may be measured to determine whether the potential agonist orantagonist is effective.

[0077] Another such screening technique involves introducing RNAencoding the G-protein coupled receptor into xenopus oocytes totransiently express the receptor. The receptor oocytes may then becontacted in the case of antagonist screening with the receptor ligandand a compound to be screened, followed by detection of inhibition of acalcium signal.

[0078] Another screening technique involves expressing the G-proteincoupled receptor in which the receptor is linked to a phospholipase C orD. As representative examples of such cells, there may be mentionedendothelial cells, smooth muscle cells, embryonic kidney cells, etc. Thescreening for an antagonist or agonist may be accomplished ashereinabove described by detecting activation of the receptor orinhibition of activation of the receptor from the phospholipase secondsignal.

[0079] Another method involves screening for antagonists by determininginhibition of binding of labeled ligand to cells which have the receptoron the surface thereof. Such a method involves transfecting a eukaryoticcell with DNA encoding the G-protein coupled receptor such that the cellexpresses the receptor on its surface and contacting the cell with apotential antagonist in the presence of a labeled form of a knownligand. The ligand can be labeled, e.g., by radioactivity. The amount oflabeled ligand bound to the receptors is measured, e.g., by measuringradioactivity of the receptors. If the potential antagonist binds to thereceptor as determined by a reduction of labeled ligand which binds tothe receptors, the binding of labeled ligand to the receptor isinhibited.

[0080] The present invention also provides a method for determiningwhether a ligand not known to be capable of binding to a G-proteincoupled receptor can bind to such receptor which comprises contacting amammalian cell which expresses a G-protein coupled receptor with theligand under conditions permitting binding of ligands to the G-proteincoupled receptor, detecting the presence of a ligand which binds to thereceptor and thereby determining whether the ligand binds to theG-protein coupled receptor. The systems hereinabove described fordetermining agonists and/or antagonists may also be employed fordetermining ligands which bind to the receptor.

[0081] In general, antagonists for G-protein coupled receptors which aredetermined by screening procedures may be employed for a variety oftherapeutic purposes. For example, such antagonists have been employedfor treatment of hypertension, angina pectoris, myocardial infarction,ulcers, asthma, allergies, psychoses, depression, migraine, vomiting,and benign prostatic hypertrophy.

[0082] In general, antagonists for G-protein coupled receptors which aredetermined by screening procedures may be employed for a variety oftherapeutic purposes. For example, such antagonists have been employedfor treatment of hypertension, angina pectoris, myocardial infarction,ulcers, asthma, allergies, psychoses, depression, migraine, vomiting,and benign prostatic hypertrophy.

[0083] Agonists for G-protein coupled receptors are also useful fortherapeutic purposes, such as the treatment of asthma, Parkinson'sdisease, acute heart failure, hypotension, urinary retention, andosteoporosis.

[0084] A potential antagonist is an antibody, or in some cases anoligonucleotide, which binds to the G-protein coupled receptor but doesnot elicit a second messenger response such that the activity of theG-protein coupled receptor is prevented. Potential antagonists alsoinclude proteins which are closely related to the ligand of theG-protein coupled receptor, i.e. a fragment of the ligand, which havelost biological function and when binding to the G-protein coupledreceptor, elicit no response.

[0085] A potential antagonist also includes an antisense constructprepared through the use of antisense technology. Antisense technologycan be used to control gene expression through triple-helix formation oranti sense DNA or RNA, both of which methods are based on binding of apolynucleotide to DNA or RNA. For example, the 5′ coding portion of thepolynucleotide sequence, which encodes for the mature polypeptides ofthe present invention, is used to design an antisense RNAoligonucleotide of from about 10 to 40 base pairs in length. A DNAoligonucleotide is designed to be complementary to a region of the geneinvolved in transcription (triple helix—see Lee et al., Nucl. AcidsRes., 6:3073 (1979); Cooney et al, Science, 241:456 (1988); and Dervanet al., Science, 251: 1360 (1991)), thereby preventing transcription andthe production of G-protein coupled receptors. The antisense RNAoligonucleotide hybridizes to the mRNA in vivo and blocks translation ofthe mRNA molecule into the G-protein coupled receptors (antisense—Okano,J. Neurochem., 56:560 (1991); Oligodeoxynucleotides as AntisenseInhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). Theoligonucleotides described above can also be delivered to cells suchthat the antisense RNA or DNA may be expressed in vivo to inhibitproduction of G-protein coupled receptors.

[0086] Another potential antagonist is a small molecule which binds tothe G-protein coupled receptor, making it inaccessible to ligands suchthat normal biological activity is prevented. Examples of smallmolecules include but are not limited to small peptides or peptide-likemolecules.

[0087] Potential antagonists also include a soluble form of a G-proteincoupled receptor, e.g. a fragment of the receptor, which binds to theligand and prevents the ligand from interacting with membrane boundG-protein coupled receptors.

[0088] The G-protein coupled receptor of the present invention has beenputatively identified as an adrenergic receptor. This identification hasbeen made as a result of amino acid sequence homology.

[0089] The antagonists may be used to treat hypertension by controllingβ-adrenergic receptors from stimulating cardiac contractility andlowering heart rate. The antagonists may also be used to preventvasoconstriction controlled by α-adrenergic receptors. The antagonistsmay be employed in a composition with a pharmaceutically acceptablecarrier, e.g., as hereinafter described.

[0090] The agonists identified by the screening method as describedabove, may be employed to stimulate the α-adrenergic receptor for thetreatment of upper respiratory conditions, e.g. allergic rhinitis, hayfever, acute coryza and sinusitis. Stimulating the α-adrenergicreceptors constricts the nasal mucosal blood vessels, lesseningsecretions, and edema. α-adrenergic receptors also control pupildilation and uterine inhibition, therefore, the agonists may also beused to stimulate those actions.

[0091] β-Adrenergic receptors mediate vasorelaxation. Stimulatingβ-adrenergic receptors by the administration of an agonist may be usedto treat bronchial asthma by causing bronchial smooth muscle relaxationand modulating mediator release, at least in part by stimulating theadenylate cyclase-cAMP system. Stimulating β-adrenergic receptors andconsequent vasorelaxation may also be used to treat coronary arterydisease, atherosclerosis and arteriosclerosis.

[0092] The adrenergic receptor and antagonists or agonists may beemployed in combination with a suitable pharmaceutical carrier. Suchcompositions comprise a therapeutically effective amount of thepolypeptide, and a pharmaceutically acceptable carrier or excipient.Such a carrier includes but is not limited to saline, buffered saline,dextrose, water, glycerol, ethanol, and combinations thereof. Theformulation should suit the mode of administration.

[0093] The invention also provides a pharmaceutical pack or kitcomprising one or more containers filled with one or more of theingredients of the pharmaceutical compositions of the invention.Associated with such container(s) can be a notice in the form prescribedby a governmental agency regulating the manufacture, use or sale ofpharmaceuticals or biological products, which notice reflects approvalby the agency of manufacture, use or sale for human administration. Inaddition, the polypeptides of the present invention may be employed inconjunction with other therapeutic compounds.

[0094] The pharmaceutical compositions may be administered in aconvenient manner such as by the topical, intravenous, intraperitoneal,intramuscular, subcutaneous, intranasal or intradermal routes. Thepharmaceutical compositions are administered in an amount which iseffective for treating and/or prophylaxis of the specific indication. Ingeneral, the pharmaceutical compositions will be administered in anamount of at least about 10 μg/kg body weight and in most cases theywill be administered in an amount not in excess of about 8 mg/Kg bodyweight per day. In most cases, the dosage is from about 10 μg/kg toabout 1 mg/kg body weight daily, taking into account the routes ofadministration, symptoms, etc.

[0095] The adrenergic receptor polypeptides and antagonists or agonistswhich are polypeptides, may be employed in accordance with the presentinvention by expression of such polypeptides in vivo, which is oftenreferred to as “gene therapy.”

[0096] Thus, for example, cells from a patient may be engineered with apolynucleotide (DNA or RNA) encoding a polypeptide ex vivo, with theengineered cells then being provided to a patient to be treated with thepolypeptide. Such methods are well-known in the art. For example, cellsmay be engineered by procedures known in the art by use of a retroviralparticle containing RNA encoding a polypeptide of the present invention.

[0097] Similarly, cells may be engineered in vivo for expression of apolypeptide in vivo by, for example, procedures known in the art. Asknown in the art, a producer cell for producing a retroviral particlecontaining RNA encoding the polypeptide of the present invention may beadministered to a patient for engineering cells in vivo and expressionof the polypeptide in vivo. These and other methods for administering apolypeptide of the present invention by such method should be apparentto those skilled in the art from the teachings of the present invention.For example, the expression vehicle for engineering cells may be otherthan a retrovirus, for example, an adenovirus which may be used toengineer cells in vivo after combination with a suitable deliveryvehicle.

[0098] Retroviruses from which the retroviral plasmid vectorshereinabove mentioned may be derived include, but are not limited to,Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses suchas Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leucosis virus,gibbon ape leukemia virus, human immunodeficiency virus, adenovirus,Myeloproliferative Sarcoma Virus, and mammary tumor virus. In oneembodiment, the retroviral plasmid vector is derived from Moloney MurineLeukemia Virus.

[0099] The vector includes one or more promoters. Suitable promoterswhich may be employed include, but are not limited to, the retroviralLTR; the SV40 promoter; and the human cytomegalovirus (CMV) promoterdescribed in Miller, et al., Biotechniques, Vol. 7, No. 9, 980-990(1989), or any other promoter (e.g., cellular promoters such aseukaryotic cellular promoters including, but not limited to, thehistone, pole, and β-actin promoters). Other viral promoters which maybe employed include, but are not limited to, adenovirus promoters,thymidine kinase (TK) promoters, and B19 parvovirus promoters. Theselection of a suitable promoter will be apparent to those skilled inthe art from the teachings contained herein.

[0100] The nucleic acid sequence encoding the polypeptide of the presentinvention is under the control of a suitable promoter. Suitablepromoters which may be employed include, but are not limited to,adenoviral promoters, such as the adenoviral major late promoter; orhetorologous promoters, such as the cytomegalovirus (CMV) promoter; therespiratory syncytial virus (RSV) promoter; inducible promoters, such asthe MMT promoter, the methallothionein promoter; heat shock promoters;the albumin promoter; the ApoAI promoter; human globin promoters; viralthymidine kinase promoters, such as the Herpes Simplex thymidine kinasepromoter; retroviral LTRs (including the modified retroviral LTRshereinabove described); the β-actin promoter; and human growth hormonepromoters. The promoter also may be the native promoter which controlsthe genes encoding the polypeptides.

[0101] The retroviral plasmid vector is employed to transduce packagingcell lines to form producer cell lines. Examples of packaging cellswhich may be transfected include, but are not limited to, the PE501,PA317, ψ-2, ψ-AM, PA12, T19-14X, VT-19-17-H2, ψ CRE, ψ CRIP, GP+E-86,GP+envAm12 and DAN cell lines as described in Miller, Human GeneTherapy, Vol. 1, pgs. 5-14 (1990), which is incorporated herein byreference in its entirety. The vector may transduce the packaging cellsthrough any means known in the art. Such means include, but are notlimited to, electroporation, the use of liposomes, and CaPO₄precipitation. In one alternative, the retroviral plasmid vector may beencapsulated into a liposome, or coupled to a lipid, and thenadministered to a host.

[0102] The producer cell line generates infectious retroviral vectorparticles which include the nucleic acid sequence(s) encoding thepolypeptides. Such retroviral vector particles then may be employed, totransduce eukaryotic cells, either in vitro or in vivo. The tranducedeukaryotic cells will express the nucleic acid sequence(s) encoding thepolypeptide. Eukaryotic cells which may be transduced include, but arenot limited to, embryonic stem cells, embryonic carcinoma cells, as wellas hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts,keratinocytes, endothelial cells, and bronchial epithelial cells.

[0103] The present invention also provides a method for determiningwhether a ligand not known to be capable of binding to a G-proteincoupled receptor can bind to such receptor which comprises contacting amammalian cell which expressed a G-protein coupled receptor with theligand under conditions permitting binding of ligands to the G-proteincoupled receptor, detecting the presence of a ligand which binds to thereceptor and thereby determining whether the ligand binds to theG-protein coupled receptor. The systems hereinabove described fordetermining agonists and/or antagonists may also be employed fordetermining ligands which bind to the receptor.

[0104] This invention also provides a method of detecting expression ofa receptor polypeptide of the present invention on the surface of a cellby detecting the presence of mRNA coding for the receptor whichcomprises obtaining total mRNA from the cell and contacting the mRNA soobtained with a nucleic acid probe comprising a nucleic acid molecule ofat least 10 nucleotides capable of specifically hybridizing with asequence included within the sequence of a nucleic acid moleculeencoding the receptor under hybridizing conditions, detecting thepresence of mRNA hybridized to the probe, and thereby detecting theexpression of the receptor by the cell.

[0105] The present invention also provides for a method for identifyingreceptors related to the receptor polypeptides of the present invention.These related receptors may be identified by homology to a receptorpolypeptide of the present invention, by low stringency crosshybridization, or by identifying receptors that interact with relatednatural or synthetic ligands and or elicit similar behaviors aftergenetic or pharmacological blockade of the receptor polypeptides of thepresent invention.

[0106] The present invention also contemplates the use of the genes ofthe present invention as a diagnostic, for example, some diseases resultfrom inherited defective genes. These genes can be detected by comparingthe sequences of the defective gene with that of a normal one.Subsequently, one can verify that a “mutant” gene is associated withabnormal receptor activity. In addition, one can insert mutant receptorgenes into a suitable vector for expression in a functional assay system(e.g., colorimetric assay, expression on MacConkey plates,complementation experiments, in a receptor deficient strain of HEK293cells) as yet another means to verify or identify mutations. Once“mutant” genes have been identified, one can then screen population forcarriers of the “mutant” receptor gene.

[0107] Individuals carrying mutations in the gene of the presentinvention may be detected at the DNA level by a variety of techniques.Nucleic acids used for diagnosis may be obtained from a patient's cells,including but not limited to such as from blood, urine, saliva, tissuebiopsy and autopsy material. The genomic DNA may be used directly fordetection or may be amplified enzymatically by using PCR (Saiki, et al.,Nature, 324:163-166 1986) prior to analysis. RNA or cDNA may also beused for the same purpose. As an example, PCR primers complimentary tothe nucleic acid of the instant invention can be used to identify andanalyze mutations in the gene of the present invention. For example,deletions and insertions can be detected by a change in size of theamplified product in comparison to the normal genotype. Point mutationscan be identified by hybridizing amplified DNA to radio labeled antisense DNA sequences of the invention. Perfectly matched sequences can bedistinguished from mismatched duplexes by RNase A digestion or bydifferences in melting temperatures. Such diagnostic would beparticularly useful for prenatal or even neonatal testing.

[0108] Sequence differences between the reference gene and “mutants” maybe revealed by the direct DNA sequencing method. In addition, cloned DNAsegments may be used as probes to detect specific DNA segments. Thesensitivity of this method is greatly enhanced when combined with PCR.For example, a sequence primer is used with double stranded PCR productor a single stranded template molecule generated by a modified PCR. Thesequence determination is performed by conventional procedures withradio labeled nucleotide or by an automatic sequencing procedure withfluorescent-tags.

[0109] Genetic testing based on DNA sequence differences may be achievedby detection of alterations in the electrophoretic mobility of DNAfragments in gels with or without denaturing agents. Sequences changesat specific locations may also be revealed by nucleus protection assays,such as RNase and S1 protection or the chemical cleavage method (e.g.,Cotton, et al., PNAS, USA, 85:4397-4401 1985).

[0110] In addition, some diseases are a result of, or are characterizedby changes in gene expression which can be detected by changes in themRNA. Alternatively, the genes of the present invention can be used as areference to identify individuals expressing a decrease of functionsassociated with receptors of this type.

[0111] The present invention also relates to a diagnostic assay fordetecting altered levels of soluble forms of the receptor polypeptidesof the present invention in various tissues. Assays used to detectlevels of the soluble receptor polypeptides in a sample derived from ahost are well known to those of skill in the art and includeradioimmunoassays, competitive-binding assays, Western blot analysis andpreferably an ELISA assay.

[0112] An ELISA assay initially comprises preparing an antibody specificto antigens of the receptor polypeptides, preferably a monoclonalantibody. In addition a reporter antibody is prepared against themonoclonal antibody. To the reporter antibody is attached a detectablereagent such as radioactivity, fluorescence or in this example ahorseradish peroxidase enzyme. A sample is now removed from a host andincubated on a solid support, e.g. a polystyrene dish, that binds theproteins in the sample. Any free protein binding sites on the dish arethen covered by incubating with a non-specific protein such as bovineserum albumin. Next, the monoclonal antibody is incubated in the dishduring which time the monoclonal antibodies attach to any receptorproteins attached to the polystyrene dish. All unbound monoclonalantibody is washed out with buffer. The reporter antibody linked tohorseradish peroxidase is now placed in the dish resulting in binding ofthe reporter antibody to any monoclonal antibody bound to receptorproteins. Unattached reporter antibody is then washed out. Peroxidasesubstrates are then added to the dish and the amount of color developedin a given time period is a measurement of the amount of receptorproteins present in a given volume of patient sample when comparedagainst a standard curve.

[0113] The sequences of the present invention are also valuable forchromosome identification. The sequence is specifically targeted to andcan hybridize with a particular location on an individual humanchromosome. Moreover, there is a current need for identifying particularsites on the chromosome. Few chromosome marking reagents based on actualsequence data (repeat polymorphisms) are presently available for markingchromosomal location. The mapping of DNAs to chromosomes according tothe present invention is an important first step in correlating thosesequences with genes associated with disease.

[0114] Briefly, sequences can be mapped to chromosomes by preparing PCRprimers (preferably 15-25 bp) from the cDNA. Computer analysis of thecDNA is used to rapidly select primers that do not span more than oneexon in the genomic DNA, thus complicating the amplification process.These primers are then used for PCR screening of somatic cell hybridscontaining individual human chromosomes. Only those hybrids containingthe human gene corresponding to the primer will yield an amplifiedfragment.

[0115] PCR mapping of somatic cell hybrids is a rapid procedure forassigning a particular DNA to a particular chromosome. Using the presentinvention with the same oligonucleotide primers, sublocalization can beachieved with panels of fragments from specific chromosomes or pools oflarge genomic clones in an analogous manner. Other mapping strategiesthat can similarly be used to map to its chromosome include in situhybridization, prescreening with labeled flow-sorted chromosomes andpreselection by hybridization to construct chromosome specific-cDNAlibraries.

[0116] Fluorescence in situ hybridization (FISH) of a cDNA clone to ametaphase chromosomal spread can be used to provide a precisechromosomal location in one step. This technique can be used with cDNAas short as 50 or 60 bases. For a review of this technique, see Verma etal., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press,New York (1988).

[0117] Once a sequence has been mapped to a precise chromosomallocation, the physical position of the sequence on the chromosome can becorrelated with genetic map data. Such data are found, for example, inV. McKusick, Mendelian Inheritance in Man (available on line throughJohns Hopkins University Welch Medical Library). The relationshipbetween genes and diseases that have been mapped to the same chromosomalregion are then identified through linkage analysis (coinheritance ofphysically adjacent genes).

[0118] Next, it is necessary to determine the differences in the cDNA orgenomic sequence between affected and unaffected individuals. If amutation is observed in some or all of the affected individuals but notin any normal individuals, then the mutation is likely to be thecausative agent of the disease.

[0119] With current resolution of physical mapping and genetic mappingtechniques, a cDNA precisely localized to a chromosomal regionassociated with the disease could be one of between 50 and 500 potentialcausative genes. (This assumes 1 megabase mapping resolution and onegene per 20 kb).

[0120] The polypeptides, their fragments or other derivatives, oranalogs thereof, or cells expressing them can be used as an immunogen toproduce antibodies thereto. These antibodies can be, for example,polyclonal or monoclonal antibodies. The present invention also includeschimeric, single chain, and humanized antibodies, as well as Fabfragments, or the product of an Fab expression library. Variousprocedures known in the art may be used for the production of suchantibodies and fragments.

[0121] Antibodies generated against the polypeptides corresponding to asequence of the present invention can be obtained by direct injection ofthe polypeptides into an animal or by administering the polypeptides toan animal, preferably a nonhuman. The antibody so obtained will thenbind the polypeptides itself. In this manner, even a sequence encodingonly a fragment of the polypeptides can be used to generate antibodiesbinding the whole native polypeptides. Such antibodies can then be usedto isolate the polypeptide from tissue expressing that polypeptide.

[0122] For preparation of monoclonal antibodies, any technique whichprovides antibodies produced by continuous cell line cultures can beused. Examples include the hybridoma technique (Kohler and Milstein,1975, Nature, 256:495-497), the trioma technique, the human B-cellhybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), andthe EBV-hybridoma technique to produce human monoclonal antibodies(Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, AlanR. Liss, Inc., pp. 77-96).

[0123] Techniques described for the production of single chainantibodies (U.S. Pat. No. 4,946,778) can be adapted to produce singlechain antibodies to immunogenic polypeptide products of this invention.Also, transgenic mice may be used to express humanized antibodies toimmunogenic polypeptide products of this invention.

[0124] The present invention will be further described with reference tothe following examples; however, it is to be understood that the presentinvention is not limited to such examples. All parts or amounts, unlessotherwise specified, are by weight.

[0125] In order to facilitate understanding of the following examplescertain frequently occurring methods and/or terms will be described.

[0126] “Plasmids” are designated by a lower case p preceded and/orfollowed by capital letters and/or numbers. The starting plasmids hereinare either commercially available, publicly available on an unrestrictedbasis, or can be constructed from available plasmids in accord withpublished procedures. In addition, equivalent plasmids to thosedescribed are known in the art and will be apparent to the ordinarilyskilled artisan.

[0127] “Digestion” of DNA refers to catalytic cleavage of the DNA with arestriction enzyme that acts only at certain sequences in the DNA. Thevarious restriction enzymes used herein are commercially available andtheir reaction conditions, cofactors and other requirements were used aswould be known to the ordinarily skilled artisan. For analyticalpurposes, typically 1 μg of plasmid or DNA fragment is used with about 2units of enzyme in about 20 μl of buffer solution. For the purpose ofisolating DNA fragments for plasmid construction, typically 5 to 50 μgof DNA are digested with 20 to 250 units of enzyme in a larger volume.Appropriate buffers and substrate amounts for particular restrictionenzymes are specified by the manufacturer. Incubation times of about 1hour at 37° C. are ordinarily used, but may vary in accordance with thesupplier's instructions.

[0128] “Oligonucleotides” refers to either a single strandedpolydeoxynucleotide or two complementary polydeoxynucleotide strandswhich may be chemically synthesized. Such synthetic oligonucleotideshave no 5′ phosphate and thus will not ligate to another oligonucleotidewithout adding a phosphate with an ATP in the presence of a kinase. Asynthetic oligonucleotide will ligate to a fragment that has not beendephosphorylated.

[0129] “Ligation” refers to the process of forming phosphodiester bondsbetween two double stranded nucleic acid fragments (Maniatis, T., etal., Id., p. 146). Unless otherwise provided, ligation may beaccomplished using known buffers and conditions with 10 units of T4 DNAligase (“ligase”) per 0.5 μg of approximately equimolar amounts of theDNA fragments to be ligated.

[0130] Unless otherwise stated, transformation was performed asdescribed in the method of Graham, F. and Van der Eb, A., Virology,52:456-457 (1973).

EXAMPLE 1

[0131] Bacterial Expression and Purification of Adrenergic Receptor

[0132] The DNA sequence encoding the adrenergic receptor, ATCC # 75822,is initially amplified using PCR oligonucleotide primers correspondingto the 5′ and 3′ sequences of the processed protein (minus the signalpeptide sequence) and the vector sequences 3′ to the adrenergic receptorgene. Additional nucleotides corresponding to the adrenergic receptorcoding sequence were added to the 5′ and 3′ sequences respectively. The5′ oligonucleotide primer has the sequence 5′CCCACCCCACGCCGAGGTGCAGGTGCAGGATCCATGAGCCTCAAC 3′ (SEQ ID NO:3) containsa BamHI restriction enzyme site (bold) followed by 9 nucleotides of theadrenergic receptor coding sequence starting from the presumed terminalamino acid of the processed protein codon. The 3′ sequence 5′CAGCCCCACGGCACCCTCTAGACCTCATCTCTGCTCGGCAGCT 3′ (SEQ ID NO:4) containscomplementary sequences to an XbaI site and is followed by 21nucleotides of the adrenergic receptor coding sequence. The restrictionenzyme sites correspond to the restriction enzyme sites on the bacterialexpression vector pQE-9 (Qiagen, Inc. 9259 Eton Avenue, Chatsworth,Calif., 91311). pQE-9 encodes antibiotic resistance (Amp^(r)), abacterial origin of replication (ori), an IPTG-regulatable promoteroperator (P/O), a ribosome binding site (RBS), a 6-His tag andrestriction enzyme sites. pQE-9 was then digested with BamHI and XbaI.The amplified sequences were ligated into pQE-9 and were inserted inframe with the sequence encoding for the histidine tag and the RBS. Theligation mixture was then used to transform E. coli strain availablefrom Qiagen under the trademark M15/rep 4 by the procedure described inSambrook, J. et al., Molecular Cloning: A Laboratory Manual, Cold SpringLaboratory Press, (1989). M15/rep4 contains multiple copies of theplasmid pREP4, which expresses the lacI repressor and also conferskanamycin resistance (Kan^(r)). Transformants are identified by theirability to grow on LB plates and ampicillin/kanamycin resistant colonieswere selected. Plasmid DNA was isolated and confirmed by restrictionanalysis. Clones containing the desired constructs were grown overnight(O/N) in liquid culture in LB media supplemented with both Amp (100ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a largeculture at a ratio of 1:100 to 1:250. The cells were grown to an opticaldensity 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG(“Isopropyl-B-D-thiogalacto pyranoside”) was then added to a finalconcentration of 1 mM. IPTG induces by inactivating the lacI repressor,clearing the P/O leading to increased gene expression. Cells were grownan extra 3 to 4 hours. Cells were then harvested by centrifugation. Thecell pellet was solubilized in the chaotropic agent 6 Molar GuanidineHCl. After clarification, solubilized adrenergic receptor protein waspurified from this solution by chromatography on a Nickel-Chelate columnunder conditions that allow for tight binding by proteins containing the6-His tag (Hochuli, E. et al., J. Chromatography 411:177-184 (1984)).The adrenergic receptor protein was eluted from the column in 6 molarguanidine HCl pH 5.0 and for the purpose of renaturation adjusted to 3molar guanidine HCl, 100 mM sodium phosphate, 10 mmolar glutathione(reduced) and 2 mmolar glutathione (oxidized). After incubation in thissolution for 12 hours the protein was dialyzed to 10 mmolar sodiumphosphate.

EXAMPLE 2

[0133] Expression of Recombinant Adrenergic Receptor in COS Cells

[0134] The expression of plasmid, pAdrenergic Receptor HA is derivedfrom a vector pcDNAI/Amp (Invitrogen) containing: 1) SV40 origin ofreplication, 2) ampicillin resistance gene, 3) E.coli replicationorigin, 4) CMV promoter followed by a polylinker region, a SV40 intronand polyadenylation site. A DNA fragment encoding the entire adrenergicreceptor precursor and a HA tag fused in frame to its 3′ end was clonedinto the polylinker region of the vector, therefore, the recombinantprotein expression is directed under the CMV promoter. The HA tagcorrespond to an epitope derived from the influenza hemagglutininprotein as previously described (I. Wilson, H. Niman, R. Heighten, ACherenson, M. Connolly, and R. Lerner, 1984, Cell 37, 767). The infusionof HA tag to our target protein allows easy detection of the recombinantprotein with an antibody that recognizes the HA epitope.

[0135] The plasmid construction strategy is described as follows: TheDNA sequence encoding the adrenergic receptor, ATCC # 75822, wasconstructed by PCR on the original EST cloned using two primers: the 5′primer 5′ CCCACCCCACGCCGGGATCCACTGACCATG 3′ (SEQ ID NO:5) contains aBamHI site followed by 10 nucleotides of sequence ending at theinitiation codon; the 3′ sequence 5′CCGCTCGAGCCTTCAAGCGTAGTCTGGGACGTCGTATGGGTATCTCTGCTCGGCAGC 3′ (SEQ IDNO:6) contains complementary sequences to an EcoRI site, translationstop codon, HA tag and the last 21 nucleotides of the adrenergicreceptor coding sequence coding sequence (not including the stop codon).Therefore, the PCR product contains a BAmHI site, coding sequencefollowed by HA tag fused in frame, a translation termination stop codonnext to the HA tag, and an EcoRI site. The PCR amplified DNA fragmentand the vector, pcDNAI/Amp, were digested with BamHI and EcoRIrestriction enzyme and ligated. The ligation mixture was transformedinto E. coli strain SURE (available from Stratagene Cloning Systems,11099 North Torrey Pines Road, La Jolla, Calif. 92037) the transformedculture was plated on ampicillin media plates and resistant colonieswere selected. Plasmid DNA was isolated from transformants and examinedby restriction analysis for the presence of the correct fragment. Forexpression of the recombinant adrenergic receptor protein, COS cellswere transfected with the expression vector by DEAE-DEXTRAN method. (J.Sambrook, E. Fritsch, T. Maniatis, Molecular Cloning: A LaboratoryManual, Cold Spring Laboratory Press, (1989)). The expression of theadrenergic receptor HA protein was detected by radiolabelling andimmunoprecipitation method. (E. Harlow, D. Lane, Antibodies: ALaboratory Manual, Cold Spring Harbor Laboratory Press, (1988)). Cellswere labelled for 8 hours with ³⁵S-cysteine two days post transfection.Culture media were then collected and cells were lysed with detergent(RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40,0.5% DOC, 50 mMTris, pH7.5). (Wilson, I. et al., Id. 37:767 (1984)). Both cell lysateand culture media were precipitated with a HA specific monoclonalantibody. Proteins precipitated were analyzed on 15% SDS-PAGE gels.

EXAMPLE 3

[0136] Cloning and Expression of Adrenergic Receptor Using theBaculovirus Expression System

[0137] The DNA sequence encoding the full length adrenergic receptorprotein, ATCC # 75822, was amplified using PCR oligonucleotide primerscorresponding to the 5′ and 3′ sequences of the gene: The 5′ primer hasthe sequence 5° CCCACCCCACGCCGGGATCCACTGACCATG 3′ (SEQ ID NO:7) andcontains a BamHI restriction enzyme site (in bold) followed by 10nucleotides resembling an efficient signal for the initiation oftranslation in eukaryotic cells (J. Mol. Biol. 1987, 196, 947-950,Kozak, M.), the initiation codon for translation “ATG” is underlined).

[0138] The 3′ primer has the sequence 5′CAGCCCCACGGCACCCTCTAGACCTCATCTCTGCTCGGCAGCT 3′ (SEQ ID NO:8) andcontains the cleavage site for the restriction endonuclease XbaI and 16nucleotides complementary to the 3′ non-translated sequence of theadrenergic receptor gene. The amplified sequences were isolated from a1% agarose gel using a commercially available kit (“Geneclean,” BIO 101Inc., La Jolla, Calif.). The fragment was then digested with theendonucleases BamHI and XbaI and purified again on a 1% agarose gel.This fragment is designated F2.

[0139] The vector pRG1 (modification of pVL941 vector, discussed below)is used for the expression of the adrenergic receptor protein using thebaculovirus expression system (for review see: Summers, M. D. and Smith,G. E. 1987, A manual of methods for baculovirus vectors and insect cellculture procedures, Texas Agricultural Experimental Station Bulletin No.1555). This expression vector contains the strong polyhedrin promoter ofthe Autographa californica nuclear polyhedrosis virus (AcMNPV) followedby the recognition sites for the restriction endonucleases BamHI andXbaI. The polyadenylation site of the simian virus (SV)40 is used forefficient polyadenylation. For an easy selection of recombinant virusesthe beta-galactosidase gene from E.coli is inserted in the sameorientation as the polyhedrin promoter followed by the polyadenylationsignal of the polyhedrin gene. The polyhedrin sequences are flanked atboth sides by viral sequences for the cell-mediated homologousrecombination of cotransfected wild-type viral DNA. Many otherbaculovirus vectors could be used in place of pRG1 such as pAc373,pVL941 and pAcIM1 (Luckow, V. A. and Summers, M. D., Virology,170:31-39).

[0140] The plasmid was digested with the restriction enzymes BamHI andXbaI and then dephosphorylated using calf intestinal phosphatase byprocedures known in the art. The DNA was then isolated from a 1% agarosegel. This vector DNA is designated V2.

[0141] Fragment F2 and the dephosphorylated plasmid V2 were ligated withT4 DNA ligase. E.coli XL1Blue cells were then transformed and bacteriaidentified that contained the plasmid (pBacAdrenergic Receptor) with theadrenergic receptor gene using the enzymes BamHI and XbaI. The sequenceof the cloned fragment was confirmed by DNA sequencing.

[0142] 5 μg of the plasmid pBacAdrenergic receptor were cotransfectedwith 1.0 μg of a commercially available linearized baculovirus(“BaculoGold™ baculovirus DNA”, Pharmingen, San Diego, Calif.) using thelipofection method (Felgner et al. Proc. Natl. Acad. Sci. USA,84:7413-7417 (1987)).

[0143] 1 μg of BaculoGold™ virus DNA and 5 μg of the plasmidpBacAdrenergic Receptor were mixed in a sterile well of a microtiterplate containing 50 μl of serum free Grace's medium (Life TechnologiesInc., Gaithersburg, Md.). Afterwards 10 μl Lipofectin plus 90 μl Grace'smedium were added, mixed and incubated for 15 minutes at roomtemperature. Then the transfection mixture was added dropwise to the Sf9insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with1 ml Grace' medium without serum. The plate was rocked back and forth tomix the newly added solution. The plate was then incubated for 5 hoursat 27° C. After 5 hours the transfection solution was removed from theplate and 1 ml of Grace's insect medium supplemented with 10% fetal calfserum was added. The plate was put back into an incubator andcultivation continued at 27° C. for four days.

[0144] After four days the supernatant was collected and a plaque assayperformed similar as described by Summers and Smith (supra). As amodification an agarose gel with “Blue Gal” (Life Technologies Inc.,Gaithersburg) was used which allows an easy isolation of blue stainedplaques. (A detailed description of a “plaque assay” can also be foundin the user's guide for insect cell culture and baculovirologydistributed by Life Technologies Inc., Gaithersburg, page 9-10).

[0145] Four days after the serial dilution of the viruses was added tothe cells, blue stained plaques were picked with the tip of an Eppendorfpipette. The agar containing the recombinant viruses was thenresuspended in an Eppendorf tube containing 200 μl of Grace's medium.The agar was removed by a brief centrifugation and the supernatantcontaining the recombinant baculoviruses was used to infect Sf9 cellsseeded in 35 mm dishes. Four days later the supernatants of theseculture dishes were harvested and then stored at 4° C.

[0146] Sf9 cells were grown in Grace's medium supplemented with 10%heat-inactivated FBS. The cells were infected with the recombinantbaculovirus V-Adrenergic Receptor at a multiplicity of infection (MOI)of 2. Six hours later the medium was removed and replaced with SF900 IImedium minus methionine and cysteine (Life Technologies Inc.,Gaithersburg). 42 hours later 5 μCi of ³⁵S-methionine and 5 μCi ³⁵Scysteine (Amersham) were added. The cells were further incubated for 16hours before they were harvested by centrifugation and the labelledproteins visualized by SDS-PAGE and autoradiography.

EXAMPLE 4

[0147] Expression Via Gene Therapy

[0148] Fibroblasts are obtained from a subject by skin biopsy. Theresulting tissue is placed in tissue-culture medium and separated intosmall pieces. Small chunks of the tissue are placed on a wet surface ofa tissue culture flask, approximately ten pieces are placed in eachflask. The flask is turned upside down, closed tight and left at roomtemperature over night. After 24 hours at room temperature, the flask isinverted and the chunks of tissue remain fixed to the bottom of theflask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillinand streptomycin, is added. This is then incubated at 37° C. forapproximately one week. At this time, fresh media is added andsubsequently changed every several days. After an additional two weeksin culture, a monolayer of fibroblasts emerge. The monolayer istypsinized and scaled into larger flasks.

[0149] pMV-7 (Kirschmeier, P. T. et al, DNA, 7:219-25 (1988) flanked bythe long terminal repeats of the Moloney murine sarcoma virus, isdigested with EcoRI and HindIII and subsequently treated with calfintestinal phosphatase. The linear vector is fractionated on agarose geland purified, using glass beads.

[0150] The cDNA encoding a polypeptide of the present invention isamplified using PCR primers which correspond to the 5′ and 3′ endsequences respectively. The 5′ primer contains an EcoRI site and the 3′primer includes a HindIII site. Equal quantities of the Moloney murinesarcoma virus linear backbone and the amplified EcoRI and HindIIIfragment are added together, in the presence of T4 DNA ligase. Theresulting mixture is maintained under conditions appropriate forligation of the two fragments. The ligation mixture is used to transformbacteria HB101, which are then plated onto agar-containing kanamycin forthe purpose of confirming that the vector had the gene of interestproperly inserted.

[0151] The amphotropic pA317 or GP+am12 packaging cells are grown intissue culture to confluent density in Dulbecco's Modified Eagles Medium(DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSVvector containing the gene is then added to the media and the packagingcells are transduced with the vector. The packaging cells now produceinfectious viral particles containing the gene (the packaging cells arenow referred to as producer cells).

[0152] Fresh media is added to the transduced producer cells, andsubsequently, the media is harvested from a 10 cm plate of confluentproducer cells. The spent media, containing the infectious viralparticles, is filtered through a Millipore filter to remove detachedproducer cells and this media is then used to infect fibroblast cells.Media is removed from a sub-confluent plate of fibroblasts and quicklyreplaced with the media from the producer cells. This media is removedand replaced with fresh media. If the titer of virus is high, thenvirtually all fibroblasts will be infected and no selection is required.If the titer is low, then it is necessary to use retroviral vector thathas a selectable marker, such as neo or his.

[0153] The engineered fibroblasts are then injected into the host,either alone or after having been grown to confluence on cytodex 3microcarrier beads. The fibroblasts now produce the protein product.

[0154] Numerous modifications and variations of the present inventionare possible in light of the above teachings and, therefore, within thescope of the appended claims, the invention may be practiced otherwisethan as particularly described.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 13 <210> SEQ ID NO 1<211> LENGTH: 2481 <212> TYPE: DNA <213> ORGANISM: human <220> FEATURE:<221> NAME/KEY: CDS <222> LOCATION: (101)..(1687) <223> OTHERINFORMATION: <400> SEQUENCE: 1 ccctcccagg ttcaagcaat tctccgcctcggcctctcca gtagctggga ctacagtcgt 60 ccagcatgct ctgcccaccc cacgccgaggtgcactgacc atg agc ctc aac tcc 115 Met Ser Leu Asn Ser 1 5 tcc ctc agctgc agg aag gag ctg agt aat ctc act gag gag gag ggt 163 Ser Leu Ser CysArg Lys Glu Leu Ser Asn Leu Thr Glu Glu Glu Gly 10 15 20 ggc gaa ggg gcgtca tca tca ccc agt tca tcg cca tca ttg tca tca 211 Gly Glu Gly Ala SerSer Ser Pro Ser Ser Ser Pro Ser Leu Ser Ser 25 30 35 cca ttt ttg tct gcctgg gga aac ctg gtc atc gtg gtc acc ttg tac 259 Pro Phe Leu Ser Ala TrpGly Asn Leu Val Ile Val Val Thr Leu Tyr 40 45 50 aag aag tcc tac ctc ctcacc ctc agc aac aag ttc gtc ttc agc ctg 307 Lys Lys Ser Tyr Leu Leu ThrLeu Ser Asn Lys Phe Val Phe Ser Leu 55 60 65 act ctg tcc aac ttc ctg ctgtcc gtg ttg gtg ctg cct ttt gtg gtg 355 Thr Leu Ser Asn Phe Leu Leu SerVal Leu Val Leu Pro Phe Val Val 70 75 80 85 acg agc tcc atc cgc agg gaatgg atc ttt ggt gta gtg tgg tgc aac 403 Thr Ser Ser Ile Arg Arg Glu TrpIle Phe Gly Val Val Trp Cys Asn 90 95 100 ttc tct gcc ctc ctc tac ctgctg atc agc tct gcc agc atg cta acc 451 Phe Ser Ala Leu Leu Tyr Leu LeuIle Ser Ser Ala Ser Met Leu Thr 105 110 115 ctc ggg gtc att gcc atc gaccgc tac tat gct gtc ctg tac ccc atg 499 Leu Gly Val Ile Ala Ile Asp ArgTyr Tyr Ala Val Leu Tyr Pro Met 120 125 130 gtg tac ccc atg aag atc acaggg aac cgg gct gtg atg gca ctt gtc 547 Val Tyr Pro Met Lys Ile Thr GlyAsn Arg Ala Val Met Ala Leu Val 135 140 145 tac atc tgg ctt cac tcg ctcatc ggc tgc ctg cca ccc ctg ttt ggt 595 Tyr Ile Trp Leu His Ser Leu IleGly Cys Leu Pro Pro Leu Phe Gly 150 155 160 165 tgg tca tcc gtg gag tatggc gag aac aaa tgg atg tgt gtg gct gct 643 Trp Ser Ser Val Glu Tyr GlyGlu Asn Lys Trp Met Cys Val Ala Ala 170 175 180 tgg cac cgg gag cct ggctac acg gcc ttc tgg cag atc tgg tgt gcc 691 Trp His Arg Glu Pro Gly TyrThr Ala Phe Trp Gln Ile Trp Cys Ala 185 190 195 ctt ttc ccc ttt ctg gtcatg ctg gtg tgc tat ggc ttc atc ttc cgc 739 Leu Phe Pro Phe Leu Val MetLeu Val Cys Tyr Gly Phe Ile Phe Arg 200 205 210 gtg gcc agg gtc aag gcacgc aag gtg cac tgt ggc aca gtc gtc atc 787 Val Ala Arg Val Lys Ala ArgLys Val His Cys Gly Thr Val Val Ile 215 220 225 gtg gag gag gat gct cagagg acc ggg agg aag aac tcc agc acc tcc 835 Val Glu Glu Asp Ala Gln ArgThr Gly Arg Lys Asn Ser Ser Thr Ser 230 235 240 245 acc tcc tct tca gggagg agg agg aat gcc ttt cag ggt gtg gtc tac 883 Thr Ser Ser Ser Gly ArgArg Arg Asn Ala Phe Gln Gly Val Val Tyr 250 255 260 tcg gcc aac cag tgcaaa gcc ctc atc acc atc ctg gtg gtc ctc ggt 931 Ser Ala Asn Gln Cys LysAla Leu Ile Thr Ile Leu Val Val Leu Gly 265 270 275 gcc ttc atg gtc acctgg ggc ccc tac atg gtt gtc atc gcc tct gag 979 Ala Phe Met Val Thr TrpGly Pro Tyr Met Val Val Ile Ala Ser Glu 280 285 290 gcc ctc tgg ggg aaaagc tcc gtc tcc ccg agc ctg gag act tgg gcc 1027 Ala Leu Trp Gly Lys SerSer Val Ser Pro Ser Leu Glu Thr Trp Ala 295 300 305 aca tgg ctg tcc tttgcc agc gct gtc tgc cac ccc ctg atc tat gga 1075 Thr Trp Leu Ser Phe AlaSer Ala Val Cys His Pro Leu Ile Tyr Gly 310 315 320 325 ctc tgg aac aagaca gtt cgc aaa gaa cta ctg ggc atg tgc ttt ggg 1123 Leu Trp Asn Lys ThrVal Arg Lys Glu Leu Leu Gly Met Cys Phe Gly 330 335 340 gac cgg tat tatcgg gaa cca ttt gtg caa cga cag agg act tcc agg 1171 Asp Arg Tyr Tyr ArgGlu Pro Phe Val Gln Arg Gln Arg Thr Ser Arg 345 350 355 ctc ttc agc atttcc aac agg atc aca gac ctg ggc ctg tcc cca cac 1219 Leu Phe Ser Ile SerAsn Arg Ile Thr Asp Leu Gly Leu Ser Pro His 360 365 370 ctc act gcg ctcatg gca ggc gga cag ccc ctg ggg cac agc agc agc 1267 Leu Thr Ala Leu MetAla Gly Gly Gln Pro Leu Gly His Ser Ser Ser 375 380 385 acg ggg gac actggc ttc agc tgc tcc cag gac tca ggg aca gat atg 1315 Thr Gly Asp Thr GlyPhe Ser Cys Ser Gln Asp Ser Gly Thr Asp Met 390 395 400 405 atg ctg cttgag gac tac acg tct gat gac aac cct ccc tct cac tgc 1363 Met Leu Leu GluAsp Tyr Thr Ser Asp Asp Asn Pro Pro Ser His Cys 410 415 420 act tgc ccaccc aag aga agg agc tcg gtg aca ttt gag gat gaa gtg 1411 Thr Cys Pro ProLys Arg Arg Ser Ser Val Thr Phe Glu Asp Glu Val 425 430 435 gaa caa atcaaa gaa gct gcc aag aac tcg att ctt cat gtg aaa gct 1459 Glu Gln Ile LysGlu Ala Ala Lys Asn Ser Ile Leu His Val Lys Ala 440 445 450 gaa gta cacaag tcc ttg gac agt tac gca gca agc ttg gcc aaa gcc 1507 Glu Val His LysSer Leu Asp Ser Tyr Ala Ala Ser Leu Ala Lys Ala 455 460 465 att gag gccgaa gcc aaa atc aac tta ttt ggg gag gag gct ttg cca 1555 Ile Glu Ala GluAla Lys Ile Asn Leu Phe Gly Glu Glu Ala Leu Pro 470 475 480 485 ggg gtcttg gtt aca gca cgg act gtc ccg ggg ggc ggc ttc ggg ggc 1603 Gly Val LeuVal Thr Ala Arg Thr Val Pro Gly Gly Gly Phe Gly Gly 490 495 500 cgc cgaggc agc aga act ctt gtg agc cag agg ctg cag ttg cag agc 1651 Arg Arg GlySer Arg Thr Leu Val Ser Gln Arg Leu Gln Leu Gln Ser 505 510 515 atc gaagaa gga gat gtt tta gct gcc gag cag aga tgagggcctc 1697 Ile Glu Glu GlyAsp Val Leu Ala Ala Glu Gln Arg 520 525 agggtgccgt ggggctgcag cctgagaggctggcccgggg aggagttccc atcaccgcct 1757 gtgccgcggc cttgggagca tgtcactgtgtacagctggc cacacacagg gaaggagcag 1817 catctggtat gcagccacca ggacaaggactgaaaataat gtctacagtc cacagcttca 1877 gcatttccag agaccacatg tgagcttcttttaggtccca gtgatgggac cagaagcatc 1937 taaagcaaaa aaaaaaccaa aaaaaattctagagatgtgt ttgtggcttt tggggaggtg 1997 gggcatggga ggaccagaga cgaagggtttggaaggagac ccccacatgc atcatttcct 2057 cctcttcaca gtgtgctggg agtccagccgtgcactgtgc cagatgcctc aggaggagaa 2117 ccctccccag tgtactgtga aggatgaacacagaacttct tcctaatgaa acgcgaccgt 2177 cctggtgtct ctacatggtt gatgcggacagtgtgggacc ctcagttcta ggactggtcc 2237 gcagagaatt tacccaggtg cagtgcgcttcggagcggtc ctcagtggcg gcacctgttg 2297 gtgttaatag ggacagacac aggcctcttgcagtctggac caccctgtct acttccctac 2357 ttaaaaggtc ttgggtattt caaaagggagaaaccactta taatagtgaa gttggtaggg 2417 cagtactact ctgtttcatt tccagaattaaaaaaaaaat aaatattatt cctgcggcct 2477 gtta 2481 <210> SEQ ID NO 2 <211>LENGTH: 529 <212> TYPE: PRT <213> ORGANISM: human <400> SEQUENCE: 2 MetSer Leu Asn Ser Ser Leu Ser Cys Arg Lys Glu Leu Ser Asn Leu 1 5 10 15Thr Glu Glu Glu Gly Gly Glu Gly Ala Ser Ser Ser Pro Ser Ser Ser 20 25 30Pro Ser Leu Ser Ser Pro Phe Leu Ser Ala Trp Gly Asn Leu Val Ile 35 40 45Val Val Thr Leu Tyr Lys Lys Ser Tyr Leu Leu Thr Leu Ser Asn Lys 50 55 60Phe Val Phe Ser Leu Thr Leu Ser Asn Phe Leu Leu Ser Val Leu Val 65 70 7580 Leu Pro Phe Val Val Thr Ser Ser Ile Arg Arg Glu Trp Ile Phe Gly 85 9095 Val Val Trp Cys Asn Phe Ser Ala Leu Leu Tyr Leu Leu Ile Ser Ser 100105 110 Ala Ser Met Leu Thr Leu Gly Val Ile Ala Ile Asp Arg Tyr Tyr Ala115 120 125 Val Leu Tyr Pro Met Val Tyr Pro Met Lys Ile Thr Gly Asn ArgAla 130 135 140 Val Met Ala Leu Val Tyr Ile Trp Leu His Ser Leu Ile GlyCys Leu 145 150 155 160 Pro Pro Leu Phe Gly Trp Ser Ser Val Glu Tyr GlyGlu Asn Lys Trp 165 170 175 Met Cys Val Ala Ala Trp His Arg Glu Pro GlyTyr Thr Ala Phe Trp 180 185 190 Gln Ile Trp Cys Ala Leu Phe Pro Phe LeuVal Met Leu Val Cys Tyr 195 200 205 Gly Phe Ile Phe Arg Val Ala Arg ValLys Ala Arg Lys Val His Cys 210 215 220 Gly Thr Val Val Ile Val Glu GluAsp Ala Gln Arg Thr Gly Arg Lys 225 230 235 240 Asn Ser Ser Thr Ser ThrSer Ser Ser Gly Arg Arg Arg Asn Ala Phe 245 250 255 Gln Gly Val Val TyrSer Ala Asn Gln Cys Lys Ala Leu Ile Thr Ile 260 265 270 Leu Val Val LeuGly Ala Phe Met Val Thr Trp Gly Pro Tyr Met Val 275 280 285 Val Ile AlaSer Glu Ala Leu Trp Gly Lys Ser Ser Val Ser Pro Ser 290 295 300 Leu GluThr Trp Ala Thr Trp Leu Ser Phe Ala Ser Ala Val Cys His 305 310 315 320Pro Leu Ile Tyr Gly Leu Trp Asn Lys Thr Val Arg Lys Glu Leu Leu 325 330335 Gly Met Cys Phe Gly Asp Arg Tyr Tyr Arg Glu Pro Phe Val Gln Arg 340345 350 Gln Arg Thr Ser Arg Leu Phe Ser Ile Ser Asn Arg Ile Thr Asp Leu355 360 365 Gly Leu Ser Pro His Leu Thr Ala Leu Met Ala Gly Gly Gln ProLeu 370 375 380 Gly His Ser Ser Ser Thr Gly Asp Thr Gly Phe Ser Cys SerGln Asp 385 390 395 400 Ser Gly Thr Asp Met Met Leu Leu Glu Asp Tyr ThrSer Asp Asp Asn 405 410 415 Pro Pro Ser His Cys Thr Cys Pro Pro Lys ArgArg Ser Ser Val Thr 420 425 430 Phe Glu Asp Glu Val Glu Gln Ile Lys GluAla Ala Lys Asn Ser Ile 435 440 445 Leu His Val Lys Ala Glu Val His LysSer Leu Asp Ser Tyr Ala Ala 450 455 460 Ser Leu Ala Lys Ala Ile Glu AlaGlu Ala Lys Ile Asn Leu Phe Gly 465 470 475 480 Glu Glu Ala Leu Pro GlyVal Leu Val Thr Ala Arg Thr Val Pro Gly 485 490 495 Gly Gly Phe Gly GlyArg Arg Gly Ser Arg Thr Leu Val Ser Gln Arg 500 505 510 Leu Gln Leu GlnSer Ile Glu Glu Gly Asp Val Leu Ala Ala Glu Gln 515 520 525 Arg <210>SEQ ID NO 3 <211> LENGTH: 45 <212> TYPE: DNA <213> ORGANISM: artificialsequence <220> FEATURE: <221> NAME/KEY: primer_bind <222> LOCATION:(1)..(45) <223> OTHER INFORMATION: primer useful for PCR contains aBamHI restriction enzyme site followed by 9 nucleotides of adrenergicreceptor coding sequence starting from the presumed terminal amino acidof the processed protein codon <400> SEQUENCE: 3 cccaccccac gccgaggtgcaggtgcagga tccatgagcc tcaac 45 <210> SEQ ID NO 4 <211> LENGTH: 43 <212>TYPE: DNA <213> ORGANISM: artificial sequence <220> FEATURE: <221>NAME/KEY: primer_bind <222> LOCATION: (1)..(43) <223> OTHER INFORMATION:primer useful for PCR contains complementary sequences to an XbaI siteand is followed by 21 nucleotides of the adrenergic receptor codingsequence <400> SEQUENCE: 4 cagccccacg gcaccctcta gacctcatct ctgctcggcagct 43 <210> SEQ ID NO 5 <211> LENGTH: 30 <212> TYPE: DNA <213>ORGANISM: artificial sequence <220> FEATURE: <221> NAME/KEY: primer_bind<222> LOCATION: (1)..(30) <223> OTHER INFORMATION: primer useful for PCRcontains a BamHI restriction enzyme site followed by 10 nucleotides ofadrenergic receptor coding sequence ending at the initiation codon <400>SEQUENCE: 5 cccaccccac gccgggatcc actgaccatg 30 <210> SEQ ID NO 6 <211>LENGTH: 57 <212> TYPE: DNA <213> ORGANISM: artificial sequence <220>FEATURE: <221> NAME/KEY: primer_bind <222> LOCATION: (1)..(57) <223>OTHER INFORMATION: primer useful for PCR contains complementarysequences to an EcoRI site, translation stop codon, HA tag and the last21 nucleotides of the adrenergic receptor coding sequence (not includingthe stop codon) <400> SEQUENCE: 6 ccgctcgagc cttcaagcgt agtctgggacgtcgtatggg tatctctgct cggcagc 57 <210> SEQ ID NO 7 <211> LENGTH: 30<212> TYPE: DNA <213> ORGANISM: artificial sequence <220> FEATURE: <221>NAME/KEY: primer_bind <222> LOCATION: (1)..(30) <223> OTHER INFORMATION:primer useful for PCR contains a BamHI restriction enzyme site followedby 10 nucleotides resembling an efficient signal for the initiation oftranslation in eukaryotic cells <400> SEQUENCE: 7 cccaccccac gccgggatccactgaccatg 30 <210> SEQ ID NO 8 <211> LENGTH: 43 <212> TYPE: DNA <213>ORGANISM: artificial sequence <220> FEATURE: <221> NAME/KEY: primer_bind<222> LOCATION: (1)..(43) <223> OTHER INFORMATION: primer useful for PCRcontains a XbaI site and 16 nucleotides complementary to the 3′non-translated sequence of the adrenergic receptor gene <400> SEQUENCE:8 cagccccacg gcaccctcta gacctcatct ctgctcggca gct 43 <210> SEQ ID NO 9<211> LENGTH: 501 <212> TYPE: PRT <213> ORGANISM: human <400> SEQUENCE:9 Met Ala Ala Ala Leu Arg Ser Val Met Met Ala Gly Tyr Leu Ser Glu 1 5 1015 Trp Arg Thr Pro Thr Tyr Arg Ser Thr Glu Met Val Gln Arg Leu Arg 20 2530 Met Glu Ala Val Gln His Ser Thr Ser Thr Ala Ala Val Gly Gly Leu 35 4045 Val Val Ser Ala Gln Gly Val Gly Val Gly Val Phe Leu Ala Ala Phe 50 5560 Ile Leu Met Ala Val Ala Gly Asn Leu Leu Val Ile Leu Ser Val Ala 65 7075 80 Cys Asn Arg His Leu Gln Thr Val Thr Asn Tyr Phe Ile Val Asn Leu 8590 95 Ala Val Ala Asp Leu Leu Leu Ser Ala Thr Val Leu Pro Phe Ser Ala100 105 110 Thr Met Glu Val Leu Gly Phe Trp Ala Phe Gly Arg Ala Phe CysAsp 115 120 125 Val Trp Ala Ala Val Asp Val Leu Cys Cys Thr Ala Ser IleLeu Ser 130 135 140 Leu Cys Thr Ile Ser Val Asp Arg Tyr Val Gly Val ArgHis Ser Leu 145 150 155 160 Lys Tyr Pro Ala Ile Met Thr Glu Arg Lys AlaAla Ala Ile Leu Ala 165 170 175 Leu Leu Trp Val Val Ala Leu Val Val SerVal Gly Pro Leu Leu Gly 180 185 190 Trp Lys Glu Pro Val Pro Pro Asp GluArg Phe Cys Gly Ile Thr Glu 195 200 205 Glu Ala Gly Tyr Ala Val Phe SerSer Val Cys Ser Phe Tyr Leu Pro 210 215 220 Met Ala Val Ile Val Val MetTyr Cys Arg Val Tyr Val Val Ala Arg 225 230 235 240 Ser Thr Thr Arg SerLeu Glu Ala Gly Val Lys Arg Glu Arg Gly Lys 245 250 255 Ala Ser Glu ValVal Leu Arg Ile His Cys Arg Gly Ala Ala Thr Gly 260 265 270 Ala Asp GlyAla His Gly Met Arg Ser Ala Lys Gly His Thr Phe Arg 275 280 285 Ser SerLeu Ser Val Arg Leu Leu Lys Phe Ser Arg Glu Lys Lys Ala 290 295 300 AlaLys Thr Leu Ala Ile Val Val Gly Val Phe Val Leu Cys Trp Phe 305 310 315320 Pro Phe Phe Phe Val Leu Pro Leu Gly Ser Leu Phe Pro Gln Leu Lys 325330 335 Pro Ser Glu Gly Val Phe Lys Val Ile Phe Trp Leu Gly Tyr Phe Asn340 345 350 Ser Cys Val Asn Pro Leu Ile Tyr Pro Cys Ser Ser Arg Glu PheLys 355 360 365 Arg Ala Phe Leu Arg Leu Leu Arg Cys Gln Cys Arg Arg ArgArg Arg 370 375 380 Arg Arg Pro Leu Trp Arg Val Tyr Gly His His Trp ArgAla Ser Thr 385 390 395 400 Ser Gly Leu Arg Gln Asp Cys Ala Pro Ser SerGly Asp Ala Pro Pro 405 410 415 Gly Ala Pro Leu Ala Leu Thr Ala Leu ProAsp Pro Asp Pro Glu Pro 420 425 430 Pro Gly Thr Pro Glu Met Gln Ala ProVal Ala Ser Arg Arg Ser His 435 440 445 Pro Ala Pro Ser Ala Ser Gly GlyCys Trp Gly Arg Ser Gly Asp Pro 450 455 460 Arg Pro Ser Cys Ala Pro LysSer Pro Ala Cys Arg Thr Arg Ser Pro 465 470 475 480 Pro Gly Ala Arg SerAla Gln Arg Gln Arg Ala Pro Ser Ala Gln Arg 485 490 495 Trp Arg Leu CysPro 500 <210> SEQ ID NO 10 <211> LENGTH: 517 <212> TYPE: PRT <213>ORGANISM: human <400> SEQUENCE: 10 Met Asn Pro Asp Leu Asp Thr Gly HisAsn Thr Ser Ala Pro Ala His 1 5 10 15 Trp Gly Glu Leu Lys Asn Ala AsnPhe Thr Gly Pro Asn Gln Thr Ser 20 25 30 Ser Asn Ser Thr Leu Pro Gln LeuAsp Ile Thr Arg Ala Ile Ser Val 35 40 45 Gly Leu Val Leu Gly Ala Phe IleLeu Phe Ala Ile Val Gly Asn Ile 50 55 60 Leu Val Ile Leu Ser Val Ala CysAsn Arg His Leu Arg Thr Pro Thr 65 70 75 80 Asn Tyr Phe Ile Val Asn LeuAla Met Ala Asp Leu Leu Leu Ser Phe 85 90 95 Thr Val Leu Pro Phe Ser AlaAla Leu Glu Val Leu Gly Tyr Trp Val 100 105 110 Leu Gly Arg Ile Phe CysAsp Ile Trp Ala Ala Val Asp Val Leu Cys 115 120 125 Cys Thr Ala Ser IleLeu Ser Leu Cys Ala Ile Ser Ile Asp Arg Tyr 130 135 140 Ile Gly Val ArgTyr Ser Leu Gln Tyr Pro Thr Leu Val Thr Arg Arg 145 150 155 160 Lys AlaIle Leu Ala Leu Leu Ser Val Trp Val Leu Ser Thr Val Ile 165 170 175 SerIle Gly Pro Leu Leu Gly Trp Lys Glu Pro Ala Pro Asn Asp Asp 180 185 190Lys Glu Cys Gly Val Thr Glu Glu Pro Phe Tyr Ala Leu Phe Ser Ser 195 200205 Leu Gly Ser Phe Tyr Ile Pro Leu Ala Val Ile Leu Val Met Tyr Cys 210215 220 Arg Val Tyr Ile Val Ala Lys Arg Thr Thr Lys Asn Leu Glu Ala Gly225 230 235 240 Val Met Lys Glu Met Ser Asn Ser Lys Glu Leu Thr Leu ArgIle His 245 250 255 Ser Lys Asn Phe His Glu Asp Thr Leu Ser Ser Thr LysAla Lys Gly 260 265 270 His Asn Pro Arg Ser Ser Ile Ala Val Lys Leu PheLys Phe Ser Arg 275 280 285 Glu Lys Lys Ala Ala Lys Thr Leu Gly Ile ValVal Gly Met Phe Ile 290 295 300 Leu Cys Trp Leu Pro Phe Phe Ile Ala LeuPro Leu Gly Ser Leu Phe 305 310 315 320 Ser Thr Leu Lys Pro Pro Asp AlaVal Phe Lys Val Val Phe Trp Leu 325 330 335 Gly Tyr Phe Asn Ser Cys LeuAsn Pro Ile Ile Tyr Pro Cys Ser Ser 340 345 350 Lys Glu Phe Lys Arg AlaPhe Val Arg Ile Leu Gly Cys Gln Cys Arg 355 360 365 Gly Arg Arg Arg ArgArg Arg Arg Arg Arg Leu Gly Gly Cys Ala Tyr 370 375 380 Thr Tyr Arg ProTrp Thr Arg Gly Gly Ser Leu Glu Arg Ser Gln Ser 385 390 395 400 Arg LysAsp Ser Leu Asp Asp Ser Gly Ser Cys Leu Ser Gly Ser Gln 405 410 415 ArgThr Leu Pro Ser Ala Ser Pro Ser Pro Gly Tyr Leu Gly Arg Gly 420 425 430Ala Pro Pro Pro Val Glu Leu Cys Ala Phe Pro Glu Trp Lys Ala Pro 435 440445 Gly Ala Leu Leu Ser Leu Pro Ala Pro Glu Pro Pro Gly Arg Arg Gly 450455 460 Arg His Asp Ser Gly Pro Leu Phe Thr Phe Lys Leu Leu Thr Glu Pro465 470 475 480 Glu Ser Pro Gly Thr Asp Gly Gly Ala Ser Asn Gly Gly CysGlu Pro 485 490 495 Arg His Val Ala Asn Gly Gln Pro Gly Phe Lys Ser AsnMet Pro Leu 500 505 510 Ala Pro Gly Gln Phe 515 <210> SEQ ID NO 11 <211>LENGTH: 466 <212> TYPE: PRT <213> ORGANISM: human <400> SEQUENCE: 11 MetVal Phe Leu Ser Gly Asn Ala Ser Asp Ser Ser Asn Cys Thr Gln 1 5 10 15Pro Pro Ala Pro Val Asn Ile Ser Lys Ala Ile Leu Leu Gly Val Ile 20 25 30Leu Gly Gly Leu Ile Leu Phe Gly Val Leu Gly Asn Ile Leu Val Ile 35 40 45Leu Ser Val Ala Cys His Arg His Leu His Ser Val Thr His Tyr Tyr 50 55 60Ile Val Asn Leu Ala Val Ala Asp Leu Leu Leu Thr Ser Thr Val Leu 65 70 7580 Pro Phe Ser Ala Ile Phe Glu Val Leu Gly Tyr Trp Ala Phe Gly Arg 85 9095 Val Phe Cys Asn Ile Trp Ala Ala Val Asp Val Leu Cys Cys Thr Ala 100105 110 Ser Ile Met Gly Leu Cys Ile Ile Ser Ile Asp Arg Tyr Ile Gly Val115 120 125 Ser Tyr Pro Leu Arg Tyr Pro Thr Ile Val Thr Gln Arg Arg GlyLeu 130 135 140 Met Ala Leu Leu Cys Val Trp Ala Leu Ser Leu Val Ile SerIle Gly 145 150 155 160 Pro Leu Phe Gly Trp Arg Gln Pro Ala Pro Glu AspGlu Thr Ile Cys 165 170 175 Gln Ile Asn Glu Glu Pro Gly Tyr Val Leu PheSer Ala Leu Gly Ser 180 185 190 Phe Tyr Leu Pro Leu Ala Ile Ile Leu ValMet Tyr Cys Arg Val Tyr 195 200 205 Val Val Ala Lys Arg Glu Ser Arg GlyLeu Lys Ser Gly Leu Lys Thr 210 215 220 Asp Lys Ser Asp Ser Glu Gln ValThr Leu Arg Ile His Arg Lys Asn 225 230 235 240 Ala Pro Ala Gly Gly SerGly Met Ala Ser Ala Lys Thr Lys Thr His 245 250 255 Phe Ser Val Arg LeuLeu Lys Phe Ser Arg Glu Lys Lys Ala Ala Lys 260 265 270 Thr Leu Gly IleVal Val Gly Cys Phe Val Leu Cys Trp Leu Pro Phe 275 280 285 Phe Leu ValMet Pro Ile Gly Ser Phe Phe Pro Asp Phe Lys Pro Ser 290 295 300 Glu ThrVal Phe Lys Ile Val Phe Trp Leu Gly Tyr Leu Asn Ser Cys 305 310 315 320Ile Asn Pro Ile Ile Tyr Pro Cys Ser Ser Gln Glu Phe Lys Lys Ala 325 330335 Phe Gln Asn Val Leu Arg Ile Gln Cys Leu Arg Arg Lys Gln Ser Ser 340345 350 Lys His Ala Leu Gly Tyr Thr Leu His Pro Pro Ser Gln Ala Val Glu355 360 365 Gly Gln His Lys Asp Met Val Arg Ile Pro Val Gly Ser Arg GluThr 370 375 380 Phe Tyr Arg Ile Ser Lys Thr Asp Gly Val Cys Glu Trp LysPhe Phe 385 390 395 400 Ser Ser Met Pro Arg Gly Ser Ala Arg Ile Thr ValSer Lys Asp Gln 405 410 415 Ser Ser Cys Thr Thr Ala Arg Val Arg Ser LysSer Phe Leu Glu Val 420 425 430 Cys Cys Cys Val Gly Pro Ser Thr Pro SerLeu Asp Lys Asn His Gln 435 440 445 Val Pro Thr Ile Lys Val His Thr IleSer Leu Ser Glu Asn Gly Glu 450 455 460 Glu Val 465 <210> SEQ ID NO 12<211> LENGTH: 413 <212> TYPE: PRT <213> ORGANISM: human <400> SEQUENCE:12 Met Gly Gln Pro Gly Asn Gly Ser Ala Phe Leu Leu Ala Pro Asn Arg 1 510 15 Ser His Ala Pro Asp His Asp Val Thr Gln Gln Arg Asp Glu Val Trp 2025 30 Val Val Gly Met Gly Ile Val Met Ser Leu Ile Val Leu Ala Ile Val 3540 45 Phe Gly Asn Val Leu Val Ile Thr Ala Ile Ala Lys Phe Glu Arg Leu 5055 60 Gln Thr Val Thr Asn Tyr Phe Ile Thr Ser Leu Ala Cys Ala Asp Leu 6570 75 80 Val Met Gly Leu Ala Val Val Pro Phe Gly Ala Ala His Ile Leu Met85 90 95 Lys Met Trp Thr Phe Gly Asn Phe Trp Cys Glu Phe Trp Thr Ser Ile100 105 110 Asp Val Leu Cys Val Thr Ala Ser Ile Glu Thr Leu Cys Val IleAla 115 120 125 Val Asp Arg Tyr Phe Ala Ile Thr Ser Pro Phe Lys Tyr GlnSer Leu 130 135 140 Leu Thr Lys Asn Lys Ala Arg Val Ile Ile Leu Met ValTrp Ile Val 145 150 155 160 Ser Gly Leu Thr Ser Phe Leu Pro Ile Gln MetHis Trp Tyr Arg Ala 165 170 175 Thr His Gln Glu Ala Ile Asn Cys Tyr AlaAsn Glu Thr Cys Cys Asp 180 185 190 Phe Phe Thr Asn Gln Ala Tyr Ala IleAla Ser Ser Ile Val Ser Phe 195 200 205 Tyr Val Pro Leu Val Ile Met ValPhe Val Tyr Ser Arg Val Phe Gln 210 215 220 Glu Ala Lys Arg Gln Leu GlnLys Ile Asp Lys Ser Glu Gly Arg Phe 225 230 235 240 His Val Gln Asn LeuSer Gln Val Glu Gln Asp Gly Arg Thr Gly His 245 250 255 Gly Leu Arg ArgSer Ser Lys Phe Cys Leu Lys Glu His Lys Ala Leu 260 265 270 Lys Thr LeuGly Ile Ile Met Gly Thr Phe Thr Leu Cys Trp Leu Pro 275 280 285 Phe PheIle Val Asn Ile Val His Val Ile Gln Asp Asn Leu Ile Arg 290 295 300 LysGlu Val Tyr Ile Leu Leu Asn Trp Ile Gly Tyr Val Asn Ser Gly 305 310 315320 Phe Asn Pro Leu Ile Tyr Cys Arg Ser Pro Asp Phe Arg Ile Ala Phe 325330 335 Gln Glu Leu Leu Cys Leu Arg Arg Ser Ser Leu Lys Ala Tyr Gly Asn340 345 350 Gly Tyr Ser Ser Asn Gly Asn Thr Gly Glu Gln Ser Gly Tyr HisVal 355 360 365 Glu Gln Glu Lys Glu Asn Lys Leu Leu Cys Glu Asp Leu ProGly Thr 370 375 380 Glu Asp Phe Val Gly His Gln Gly Thr Val Pro Ser AspAsn Ile Asp 385 390 395 400 Ser Gln Gly Arg Asn Cys Ser Thr Asn Asp SerLeu Leu 405 410 <210> SEQ ID NO 13 <211> LENGTH: 359 <212> TYPE: PRT<213> ORGANISM: human <400> SEQUENCE: 13 Met Ala Pro Asn Gly Thr Ala SerSer Phe Cys Leu Asp Ser Thr Ala 1 5 10 15 Cys Lys Ile Thr Ile Thr ValVal Leu Ala Val Leu Ile Leu Ile Thr 20 25 30 Val Ala Gly Asn Val Val ValCys Leu Ala Val Gly Leu Asn Arg Arg 35 40 45 Leu Arg Asn Leu Thr Asn CysPhe Ile Val Ser Leu Ala Ile Thr Asp 50 55 60 Leu Leu Leu Gly Leu Leu ValLeu Pro Phe Ser Ala Ile Tyr Gln Leu 65 70 75 80 Ser Cys Lys Trp Ser PheGly Lys Val Phe Cys Asn Ile Tyr Thr Ser 85 90 95 Leu Asp Val Met Leu CysThr Ala Ser Ile Leu Asn Leu Phe Met Ile 100 105 110 Ser Leu Asp Arg TyrCys Ala Val Met Asp Pro Leu Arg Tyr Pro Val 115 120 125 Leu Val Thr ProVal Arg Val Ala Ile Ser Leu Val Leu Ile Trp Val 130 135 140 Ile Ser IleThr Leu Ser Phe Leu Ser Ile His Leu Gly Trp Asn Ser 145 150 155 160 ArgAsn Glu Thr Ser Lys Gly Asn His Thr Thr Ser Lys Cys Lys Val 165 170 175Gln Val Asn Glu Val Tyr Gly Leu Val Asp Gly Leu Val Thr Phe Tyr 180 185190 Leu Pro Leu Leu Ile Met Cys Ile Thr Tyr Tyr Arg Ile Phe Lys Val 195200 205 Ala Arg Asp Gln Ala Lys Arg Ile Asn His Ile Ser Ser Trp Lys Ala210 215 220 Ala Thr Ile Arg Glu His Lys Ala Thr Val Thr Leu Ala Ala ValMet 225 230 235 240 Gly Ala Phe Ile Ile Cys Trp Phe Pro Tyr Phe Thr AlaPhe Val Tyr 245 250 255 Arg Gly Leu Arg Gly Asp Asp Ala Ile Asn Glu ValLeu Glu Ala Ile 260 265 270 Val Leu Trp Leu Gly Tyr Ala Asn Ser Ala LeuAsn Pro Ile Leu Tyr 275 280 285 Ala Ala Leu Asn Arg Asp Phe Arg Thr GlyTyr Gln Gln Leu Phe Cys 290 295 300 Cys Arg Leu Ala Asn Arg Asn Ser HisLys Thr Ser Leu Arg Ser Asn 305 310 315 320 Ala Ser Gln Leu Ser Arg ThrGln Ser Arg Glu Pro Arg Gln Gln Glu 325 330 335 Glu Lys Pro Leu Lys LeuGln Val Trp Ser Gly Thr Glu Val Thr Ala 340 345 350 Pro Gln Gly Ala ThrAsp Arg 355

What is claimed is:
 1. An isolated polynucleotide comprising a memberselected from the group consisting of: (a) a polynucleotide encoding thepolypeptide comprising amino acid 1 to 529 as set forth in SEQ ID NO:2;(b) a polynucleotide capable of hybridizing to and which is at least 70%identical to the polynucleotide of (a); and (c) a polynucleotidefragment of the polynucleotide of (a) or (b).
 2. The polynucleotide ofclaim 1 wherein the polynucleotide is DNA.
 3. An isolated polynucleotidecomprising a member selected from the group consisting of: (a) apolynucleotide encoding a mature polypeptide encoded by the DNAcontained in ATCC Deposit No. 75822; (b) a polynucleotide encoding apolypeptide expressed by the DNA contained in ATCC Deposit No. 75822;(c) a polynucleotide capable of hybridizing to and which is at least 70%identical to the polynucleotide of (a) or (b); and (d) a polynucleotidefragment of the polynucleotide of (a), (b) or (c).
 4. A vectorcontaining the DNA of claim
 2. 5. A host cell transformed or transfectedwith the vector of claim
 4. 6. A process for producing a polypeptidecomprising: expressing from the host cell of claim 5 the polypeptideencoded by said DNA.
 7. A process for producing cells capable ofexpressing a polypeptide comprising transforming or transfecting thecells with the vector of claim
 4. 8. A receptor polypeptide comprising amember selected from the group consisting of: (i) a polypeptide havingthe deduced amino acid sequence of SEQ ID NO:2 and fragments, analogsand derivatives thereof; and (ii) a polypeptide encoded by the cDNA ofATCC Deposit No. 75822 and fragments, analogs and derivatives of saidpolypeptide.
 9. An antibody against the polypeptide of claim
 8. 10. Acompound which activates the polypeptide of claim
 8. 11. A compoundwhich inhibits activation the polypeptide of claim
 8. 12. A method forthe treatment of a patient having need to activate an adrenergicreceptor comprising: administering to the patient a therapeuticallyeffective amount of the compound of claim
 10. 13. A method for thetreatment of a patient having need to inhibit an adrenergic receptorcomprising: administering to the patient a therapeutically effectiveamount of the compound of claim
 11. 14. The method of claim 12 whereinsaid compound is a polypeptide and a therapeutically effective amount ofthe compound is administered by providing to the patient DNA encodingsaid agonist and expressing said agonists in vivo.
 15. The method ofclaim 13 wherein said compound is a polypeptide and a therapeuticallyeffective amount of the compound is administered by providing to thepatient DNA encoding said antagonist and expressing said antagonist invivo.
 16. A method for identifying compounds which bind to and activatethe receptor polypeptide of claim 8 comprising: contacting a cellexpressing on the surface thereof the receptor polypeptide, saidreceptor being associated with a second component capable of providing adetectable signal in response to the binding of a compound to saidreceptor polypeptide, with a compound under conditions sufficient topermit binding of the compound to the receptor polypeptide; andidentifying if the compound is capable of receptor binding by detectingthe signal produced by said second component.
 17. A method foridentifying compounds which bind to and inhibit activation of thepolypeptide of claim 8 comprising: contacting a cell expressing on thesurface thereof the receptor polypeptide, said receptor being associatedwith a second component capable of providing a detectable signal inresponse to the binding of a compound to said receptor polypeptide, withan analytically detectable ligand known to bind to the receptorpolypeptide and a compound to be screened under conditions to permitbinding to the receptor polypeptide; and determining whether thecompound inhibits activation of the polypeptide by detecting the absenceof a signal generated from the interaction of the ligand with thepolypeptide.
 18. A process for diagnosing a disease or a susceptibilityto a disease related to an under-expression of the polypeptide of claim8 comprising: determining a mutation in the nucleic acid sequenceencoding said polypeptide.
 19. The polypeptide of claim 8 wherein thepolypeptide is a soluble fragment of the polypeptide and is capable ofbinding a ligand for the receptor.
 20. A diagnostic process comprising:analyzing for the presence of the polypeptide of claim 19 in a samplederived from a host.
 21. An antibody or portion thereof thatspecifically binds to a protein selected from the group consisting of:(a) a protein that is encoded by a polynucleotide sequence of SEQ IDNO:1; (b) a protein consisting of amino acid residues 1 to 529 of SEQ IDNO:2; (c) a protein consisting of a first amino acid sequence which is90% or more identical to an amino acid sequence of SEQ ID NO:2; (d) aprotein consisting of a first amino acid sequence which is 95% or moreidentical to an amino acid sequence of SEQ ID NO:2; (e) a proteinconsisting of 30 contiguous amino acids of SEQ ID NO:2; and (f) aprotein consisting of 50 contiguous amino acids of SEQ ID NO:2.
 22. Theantibody or portion thereof of claim 21 which is a monoclonal antibody.23. The antibody or portion thereof of claim 21 which is a polyclonalantibody.
 24. The antibody or portion thereof of claim 21 which is achimeric antibody.
 25. The antibody or portion thereof of claim 21 whichis a humanized antibody.
 26. The antibody or portion thereof of claim 21which is an Fab fragment.
 27. The antibody or portion thereof of claim21 which is a single chain antibody.
 28. The antibody or portion thereofof claim 21 which inhibits G-protein coupled receptor activity.
 29. Theantibody or portion thereof of claim 21 which enhances G-protein coupledreceptor activity.
 30. A hybridoma cell line that produces themonoclonal antibody or portion thereof of claim
 22. 31. The hybridomacell line of claim 30 wherein the antibody or portion thereof ishumanized.
 32. A pharmaceutical composition comprising the antibody orportion thereof of claim 21 and a pharmaceutically acceptable carrier.33. The pharmaceutical composition of claim 32, wherein the antibody orportion thereof is a monoclonal antibody.
 34. The pharmaceuticalcomposition of claim 32, wherein the antibody or portion thereof ishumanized.
 35. A method of assaying G-protein coupled receptor proteinlevels in a biological sample comprising: (a) contacting a biologicalsample from a test subject with the antibody or portion thereof of claim21; and (b) detecting the level of G-protein coupled receptor protein inthe biological sample.
 36. The method of claim 35, wherein the antibodyor portion thereof is a monoclonal antibody.
 37. The method of claim 35,wherein the antibody or portion thereof is a polyclonal antibody. 38.The method of claim 35, wherein the antibody or portion thereof is asingle chain antibody.
 39. An antibody or portion thereof thatspecifically binds to a protein selected from the group consisting of:(a) a protein that is encoded by the cDNA contained in ATCC Deposit No.75822; (b) a protein consisting of a first polypeptide 90% or moreidentical to a second polypeptide encoded by the cDNA contained in ATCCDeposit No. 75822; (c) a protein consisting of a first polypeptide 95%or more identical to a second polypeptide encoded by the cDNA containedin ATCC Deposit No. 75822; (d) a protein consisting of 30 contiguousamino acid residues of a polypeptide encoded by the cDNA contained inATCC Deposit No. 75822; and (e) a protein consisting of 50 contiguousamino acid residues of a polypeptide encoded by the cDNA contained inATCC Deposit No.
 75822. 40. The antibody or portion thereof of claim 39which is a monoclonal antibody.
 41. The antibody or portion thereof ofclaim 39 which is a polyclonal antibody.
 42. The antibody or portionthereof of claim 39 which is a chimeric antibody.
 43. The antibody orportion thereof of claim 39 which is a humanized antibody.
 44. Theantibody or portion thereof of claim 39 which is an Fab fragment. 45.The antibody or portion thereof of claim 39 which is a single chainantibody.
 46. The antibody or portion thereof of claim 39 which inhibitsG-protein coupled receptor activity.
 47. The antibody or portion thereofof claim 39 which enhances G-protein coupled receptor activity.
 48. Ahybridoma cell line that produces the monoclonal antibody or portionthereof of claim
 40. 49. The hybridoma cell line of claim 48 wherein theantibody or portion thereof is humanized.
 50. A pharmaceuticalcomposition comprising the antibody or portion thereof of claim 39 and apharmaceutically acceptable carrier.
 51. The pharmaceutical compositionof claim 39, wherein the antibody or portion thereof is a monoclonalantibody.
 52. The pharmaceutical composition of claim 51, wherein theantibody or portion thereof is humanized.
 53. A method of assayingG-protein coupled receptor protein levels in a biological samplecomprising: (a) contacting a biological sample from a test subject withthe antibody or portion thereof of claim 39; and (b) detecting the levelof G-protein coupled receptor protein in the biological sample.
 54. Themethod of claim 53, wherein the antibody or portion thereof is amonoclonal antibody.
 55. The method of claim 53, wherein the antibody orportion thereof is a polyclonal antibody.
 56. The method of claim 53,wherein the antibody or portion thereof is a single chain antibody.